Multitarget small molecule inhibitors and uses thereof
Multitarget small molecule inhibitors, like those using a benzopyranone scaffold, address the limitations of current MCL treatments by simultaneously targeting CDK4/6, PI3K, and BRD4, enhancing therapeutic efficacy and reducing side effects, as seen in their potent activity against ibrutinib-resistant MCL cells.
Patent Information
- Application Number
- PCT/US2024/031549
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current cancer treatments, particularly for mantle cell lymphoma (MCL), face challenges with drug resistance and off-target toxicities due to the use of multiple inhibitors, which limits their effectiveness and patient compliance, highlighting the need for multitarget small molecule inhibitors that can simultaneously target key cell cycle pathways like CDK4/6, PI3K, and BRD4 to enhance therapeutic efficacy while minimizing side effects.
Development of compounds, such as those represented by Formula I, which are multitarget small molecule inhibitors capable of simultaneously inhibiting CDK4/6, PI3K, and BRD4, utilizing a benzopyranone scaffold to improve metabolic stability and bioavailability, thereby targeting multiple pathways to induce synthetic lethality in cancer cells, including ibrutinib-resistant MCL.
These compounds demonstrate potent activity against CDK4/6, PI3K, and BRD4, showing significant cytotoxicity and apoptosis induction in MCL cells, with improved metabolic stability and bioavailability, potentially offering a more effective and safer treatment option by targeting multiple pathways simultaneously.
Smart Images

Figure US2024031549_05122024_PF_FP_ABST
Abstract
Description
Multitarget Small Molecule Inhibitors and Uses ThereofCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 504,802, filed May 30, 2023, the contents of which are incorporated by reference herein.STATEMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with government support under Grant No. CA215651 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION
[0003] This invention relates to multitarget small molecule inhibitors and methods of using the same.BACKGROUND OF THE INVENTION
[0004] Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (BNHL) that is characterized by reciprocal chromosomal translocation t(l 1; 14)(ql3;q32), with subsequent overexpression of the cyclin DI (CCND1) gene (Vaandrager et al., Blood 1996). The prevalence of MCL in men is three times greater than in women, and the average age of diagnosis is 60 to 70 years of age (Fu, S. et al., Oncotarget 2017). It is one the most aggressive B cell malignancies and occurs at a rate of one to two cases per 100,000 people per year (Dreyling, M. et al., Ann. Oncol. 2017). MCL is a largely fatal disease with a median overall survival of approximately 3 to 4 years, depending on the stage at diagnosis and whether it is aggressive or indolent MCL (Kumar, A. et al., Blood Cancer J., 2019). Currently, the standard of care treatment for newly diagnosed MCL is induction chemo-immunotherapy with or without autologous stem cell transplantation (Riedell, P. A. et al., Cell Ther. 2021; Le Gouill, S. et al., N. Engl. J. Med. 2017). A recent study showed that bendamustine and rituximab chemotherapy was the front-line treatment for MCL (Narkhede, M. et al., Blood Adv. 2022). Although there is no curative standard treatment for MCL, the disease usually progresses slowly (Lee, C. et al., Hematol. Oncol. Clin. North Am. 2020). The main pathological driver of MCL, the CCND1 gene, controls the transition from G1 to S phases of the cell cycle in lymphoid and hematopoietic tissues and has become avaluable marker for diagnosis and treatment (Klapper, W., Semin. Hematol. 2011; Lee, C. et al., Ann. Lymphoma 2020).
[0005] Several MCL drugs targeting multiple specific targets have been reported so far, particularly for dual inhibitors (Duan, Y. C. et al., Eur. J. Med. Chem. 2021; Guo, Z. et al., J. Med. Chem. 2022; Lu, D. et al., J. Med. Chem. 2022). Recent reports have shown that targeting multiple kinases and epigenetic targets can enhance the potency of a therapy, while also reducing drug resistance and acute toxicities in solid tumors and lymphoid malignancies (Mazur, P. K. et al., Nat. Med. 2015; Huang, X. et al., Cell 2018). Combination therapies targeting two or more pathways constitute the backbone of modern cancer treatment to prevent resistance. However, excessive off- target toxicities from the combination of individual inhibitors are frequently observed in clinical settings, limiting this approach. Additionally, drug combination therapies have a poor pharmacokinetic profile, cause undesirable drug-drug interactions, and have poor patient compliance (Anighoro, A. et al., J. Med. Chem. 2014). The use of one small molecule drug that modulates the activity of two or more targets simultaneously to enhance the therapeutic effect of cancer treatments and avoid the drawbacks associated with combining multiple agents has seen prominence in recent in cancer research (Wang, C. et al., J. Med. Chem. 2021). Without wishing to be bound by any particular theory, combining the activity in one small molecule to simultaneously inhibit three separate targets may be the best way to maximize synthetic lethality across the broadest range of cancer cell types, to minimize off-target side effects that occur with the use of multiple drugs, and to provide cost-effective CDK4 / 6 / 9-inhibition-based cancer treatment (i.e., one drug versus two drugs).
[0006] Cyclin-dependent kinases (CDK) are a family of serine / threonine kinases, which control the cell cycle and transcription. Together with protein kinases, cyclins form active complexes that control cell proliferation, survival, and DNA repair. CDKs represent promising molecular targets for lymphoma and leukemia treatment (Franco, L. C. et al., J. Cell Biochem. 2018; Lee, D. J. et al., Expert Opin. Investig. Drugs 2019). The well-known CDK4 / 6 phosphorylates the retinoblastoma protein (Rb), which in turn controls the progression from G1 to S phase of the cell cycle. The CDK9 kinase phosphorylates the carboxy-terminal domain of RNA polymerase II (RNA Pol II) in cells to promote transcription elongation, which is especially important for genes that are driven by super-enhancers (Minzel, W. et al., Cell 2018). The PI3K / AKT pathway is involved in a variety of human diseases and cancers, including B-cell malignancies, autoimmunity, fibrosis, diabetes, heart disease, and neurological disorders (Cannon, L. et al., J. Adv. Pract. Oncol. 2019; Huang, X. et al., Int. J. Biol. Sci. 2018).
[0007] The combination of cyclin-dependent kinase (CDK) 4 / 6 inhibition with ibrutinib has been shown to be an effective therapeutic strategy for MCL. Although several CDK4 / 6 inhibitors have been approved by the FDA for various indications, these drugs are cytostatic in nature and patients treated with these agents rapidly develop resistance. A new study suggests that simultaneous inhibition of phosphatidylinositol 3-kinase (PI3K) can prevent resistance to CDK4 / 6 inhibitors (Chiron, D. et al., Cell Cycle 2013). However, CDK4 / 6-resistant cells cannot be resensitized by adding PI3K inhibitors alone, suggesting that concurrent inhibition of PI3K and CDK4 / 6 may be most effective. A recent combined CDK4 / 6 and PI3K inhibitor has been reported to cause synthetic lethality in MCL and other cancer types, including breast and neuroblastoma (Divakar, S. K. et al., Leukemia 2016). Bromodomain containing protein 4 (BRD4) represents another key targetable epigenetic pathway in cancer, including MCL (Tsukamoto, T. et al., Cancer Genomics Proteomics 2020), since BRD4 inhibition downregulates MYC and modulates Cyclin D transcription. Thus, BRD4 will likely enhance cell cycle arrest in G1 phase associated with CDK4 / 6 inhibition. Moreover, BRD4 has been reported to control “kinome adaptation,” an important mechanism for cancer cell resistance to kinase inhibitory drugs.
[0008] Thus, small molecules that are able to inhibit two or more of the aforementioned cell cycle pathways are desirable as anti-cancer therapeutics.SUMMARY
[0009] Provided herein according to some aspects of the present invention is a compound ofFormula I:or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1is an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy; 3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andXi and X2are each independently selected from the group consisting of C and N,which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0010] In some embodiments, the compound of Formula I is a compound of Formula IA:or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1is an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy;R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andX1and X2are each independently selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0011] In some embodiments, the compound of Formula IA is a compound of Formula IA(a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H, alkyl, or hydroxy;X2and X3are each independently selected from the group consisting of C and N;R4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); andtwo of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl)
[0012] In some embodiments, the compound of Formula IA(a) is a compound of Formulaor a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;X2is selected from the group consisting of C and N;R2is H or hydroxy;R4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); andX3is selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0013] In some embodiments, the compound of Formula IA is a compound of Formula IA(b):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;X1and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH;R4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0014] In some embodiments, the compound of Formula IA(b) is a compound of Formula IA(b)(i):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H or hydroxy;X3is selected from the group consisting of C and N; andR4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., tri fluoromethyl), which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0015] In some embodiments, the compound of Formula IA(b) is a compound of Formula IA(b)(ii):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Xi is N and R2is absent, or X1is C and R2is H or hydroxy;X3is C or N; andY is selected from the group consisting of O and NH, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0016] In some embodiments, the compound of Formula IA is a compound of Formula IA(c):Formula IA(c) or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H or hydroxy;X1is selected from the group consisting of C and N;(i) two of R4, R5, and R6join to form a heterocycle, and the third is H; or (ii) two of R5, R6, andR7are H or alkyl, and the third is a heterocycle; andR7is selected from the group consisting of H, alkyl, carbonyl, and alkenyl,which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0017] In some embodiments, the compound of Formula IA is a compound of Formula IA(d):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:X1is selected from the group consisting of C and N;R2is H or hydroxy;R4, R5, and R6are independently selected from the group consisting of H, halo (e.g., Cl), hydroxy, and alkoxy; and two of R7, R8, and R9join to form a heterocycle, and the third is H or alkyl, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0018] In some embodiments, the compound of Formula I is a compound of Formula IB:or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy;R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andXi is selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0019] In some embodiments, the compound of Formula IB is a compound of Formula IB(a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H, alkyl, or hydroxy; and two of R4, R5, and R6join to form a heteroaryl or heterocycle, and the third is H or alkyl, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluorom ethyl or trifluorom ethyl).
[0020] In some embodiments, the compound of Formula IB(a) is a compound of Formula IB(a)(i):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H, alkyl, or hydroxy;R7is selected from the group consisting of H, alkyl, alkoxy, cyano, amino and amide; andX3and X4are each independently selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0021] In some embodiments, the compound of Formula IB is a compound of Formula IB(b):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;R4is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide;R5and R6are each independently selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl);X2and X3are each independently selected from the group consisting of C and N; when X2is N, R5is absent; andY is selected from the group consisting of O and NH, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0022] In some embodiments, the compound of Formula IB(b) is a compound of Formula IB(b)(i):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;Y is selected from the group consisting of O and NH;X2is selected from the group consisting of C and N; when X2is N, R5is absent;R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); and one of R7and R8is H or alkyl, and the other is selected from the group consisting of cycloalkyl, heterocycle, aryl, and heteroaryl, or R7and R8join to form a heterocycle, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0023] In some embodiments, the compound of Formula IB(b)(i) is a compound of Formula IB(b)(i)(x):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;Y is selected from the group consisting of O and NH;R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl);X2is selected from the group consisting of C and N; when X2is N, R5is absent; and two of R9, Rio, and R11 join to form a heterocycle, and the third is H or alkyl, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0024] In some embodiments, the compound of Formula IB(b)(i)(x) is a compound of Formula IB(b)(i)(x)(a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl);X2is selected from the group consisting of C and N; when X2is N, R5is absent; andY is selected from the group consisting of O and NH, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0025] In some embodiments, the compound of Formula IB(b) is a compound of Formula IB(b)(ii):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy; R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl);X2and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH; and one of R7and R8is H or alkyl, and the other is selected from the group consisting of cycloalkyl, heterocycle, aryl, and heteroaryl, or R7and R8join to form a heterocycle, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0026] In some embodiments, the compound of Formula IB(b)(ii) is a compound of Formula IB(b)(ii)(x):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;X2and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH; R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); and two of R9, R10, and R11join to form a heterocycle, and the third is H or alkyl, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0027] In some embodiments, the compound of Formula IB(b)(ii)(x) is a compound of Formula IB(b)(ii)(x)(a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;X2and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH; and R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl) , which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0028] In some embodiments, the compound of Formula I is a compound of Formula IC:or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1 is an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andXi is selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
[0029] Also provided is a method of treatment for cancer comprising administering a compound as taught herein to a subject in need thereof in a therapeutically effective amount, or the use of the compound in a method for treating cancer, or for preparing a medicament for use in treating cancer.
[0030] Also provided is a method of treatment for disease (e.g., non-cancer proliferative disease, inflammatory disease, viral infection, etc.) comprising administering a compound as taught herein to a subject in need thereof in a therapeutically effective amount, or the use of the compound in a method for treating disease, or for preparing a medicament for use in treating disease.
[0031] Also provided is a composition comprising a compound as taught herein and a pharmaceutically acceptable carrier.BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Fig. 1 is a schematic showing the design strategy for a CDK4 / 6 / 9-PI3K-BRD4 multitarget inhibitor (LCI132) based on a benzopyranone (BP) scaffold compound, ribociclib, and CDK4 / 6 / 9 inhibitors (LCI133 [Table 11, S. No. 3] and LCI136 [Table 11, S. No. 29]).
[0033] Fig. 2 are images showing the predicted 2D binding interactions of LCI132 (Table 11, S. No. 1) interacting with CDK6 (panel A), CDK9 (panel B), BRD4 (panel C), and PI3Kdelta (panel D); the hydrogen bonds are represented by arrows.
[0034] Fig. 3 are images showing the predicted 2D binding interactions of LCI136 (Table 11, S. No. 29) interacting with CDK6 (panel A), CDK9 (panel B), PI3Kdelta (panel C), and PI3Kalpha (panel D); the hydrogen bonds are represented by arrows.
[0035] Fig. 4 are images showing the predicted binding interactions of LCI139 (Table 11, S. No. 33) interacting with PI3Kalpha in a 3D representation (panel A), PI3Kalpha in a 2D representation (panel B), CDK9 in a 3D representation (panel C), and CDK9 in a 2D representation (panel D); the hydrogen bonds are represented by arrows.
[0036] Fig. 5 is a series of graphs showing the CDK4 / cyclin DI and CDK6 / cyclin DI enzymatic activity IC50 curves after treatment with either LCI132 (Table 11, S. No. 1) or LCI133 (Table 11, S. No. 3).
[0037] Fig. 6 is a series of graphs showing the CDK2 / cyclin E and CDK9 / cyclin T1 enzymatic activity IC50 curves after treatment with either LCI132 (Table 11, S. No. 1) or LCI133 (Table 11, S. No. 3).
[0038] Fig. 7 is a series of graphs showing the CDK4 / cyclin DI, CDK6 / / cyclin DI, and CDK9 / cyclin T1 enzymatic activity IC50 curves after treatment with either LCI139 (Table 11, S. No. 33), LCI140 (Table 11, S. No. 32), or LCI142 (Table 11, S. No. 39).
[0039] Fig. 8 are a series of graphs showing the cytotoxicity of LCI132 (Table 11, S. No. 1) and combination of three (PLX51107, BKM-120, and ribociclib) drugs on healthy B-cells (panel A) and HS-5 stromal cells (panel B), as well as the antiproliferative activity of increasing concentrations of ibrutinib, PLX51107, ribociclib, BKM-120, LCI28 (Table 11, S. No. 46), LCI132 (Table 11, S. No. 1), and LCI133 (Table 11, S. No. 3) on of JeKo-1 cells (panel C) and Mino cells (panel D); asterisks denote significant P-values such that0.0001 and **P<0.01, while error bars represents ± SEM of three replicates.
[0040] Fig. 9 are western blots showing the protein level phosphorylated or non-phosphorylated serine / threonine protein kinases AKT and ERK (pAKT and AKT, or pERK and ERK), retinoblastoma protein (pRb), Myc, and actin after 1-hour treatments of ribociclib (10 pM), BKM- 120 (1 pM), PLX51107 (0.5 pM), LCI28 (1 pM) (Table 11, S. No. 46), and indicated concentrations of LCI132 (Table 11, S. No. 1) and LCI133 (Table 11, S. No. 3) from lysates from IgM stimulated JeKo-1 (panel A) and Mino (panel B) cells. Panel C is a table showing the percentage of DNA content at each phase of cell cycle after 1-hour treatments of ribociclib (10 pM), BKM-120 (1 pM), PLX51107 (0.5 pM), LCI28 (1 pM) (Table 11, S. No. 46), and indicated concentrations of LCI132 (Table 7, S. No. 1) and LCI133 (Table 11, S. No. 3) in JeKo-1 cells as analyzed by vibrant dye assay system (Thermo Fisher). Panel D is a western blot image of the protein level of phosphorylated pRb (either at positions S811 / 708 or S708), non-phosphorylated retinoblastoma protein (Rb), E2F transcription factor 1 (E2F1) protein, or actin from JeKo-1 cells treated with 0.5 pM of LCI132 (Table 11, S. No. 1) at initial administration (0) or after 4, 8, 12, 24, 48, or 72 hours after administration. Panels E-F are graphs showing the apoptosis induced in JeKo-1 (panel E) or Mino (panel F) cells as analyzed by flow cytometry by evaluating the percentage of Annexin V / 7AAD positively stained cells after 24-hour treatments of the indicated compounds; the error bars represent ±SD from the mean value of at least two independent cell passage experiment and asterisks denote significance by *P< 0.05.
[0041] Fig. 10 are a series of graphs showing the antiproliferative activity of increasing concentrations of ibrutinib, PLX51107, ribociclib, BKM-120, LCI28 (Table 11, S. No. 46), LCI133 (Table 11, S. No. 3), and LCI132 (Table 11, S. No. 1) on ibrutinib resistant JeKo-1 R (panel A) and Mino R (panel B) cell lines. Panel C is a graph showing the apoptosis induced in ibrutinib resistant JeKo-1 R cells as analyzed by flow cytometry by evaluating the percentage of Annexin V / 7AAD positively stained cells after 24-hour treatments of the indicated compounds;the error bars represent ±SD from the mean value of at least two independent cell passage experiment and asterisks denote significance by *P< 0.05. Panel D is a table showing the percentage of DNA content at each phase of cell cycle after 1-hour treatments of ribociclib (10 μM), BKM-120 (1 pM), PLX51107 (0.5 pM), LCI28 (1 pM) (Table 11, S. No. 46), and indicated concentrations of LCI132 (Table 7, S. No. l) and LCI133 (Table 11, S. No. 3) in ibrutinib resistant JeKo-1 R cells as analyzed by vibrant dye assay system (Thermo Fisher).
[0042] Fig. 11 is a series of graphs showing the antiproliferative activity of increasing concentrations of LCI139 (Table 11, S. No. 33) in parental JeKo-1 (JeKo-1 P), ibrutinib resistant JeKo-1 R, and Mino cells.
[0043] Fig. 12 is a graph showing the antiproliferative activity of increasing concentrations of PLX-51107, Flavopyridol, LCI139, LCI141, and LCI143 in an enzalutamide-resistant prostate cancer 22Rvl cell line.
[0044] Fig. 13 is a series of graphs showing the stability of LCI132 (Table 11, S. No. 1) and LCI136 (Table 11, S. No. 29) in mouse and human microsomes expressed as the % of compound concentration remaining (Mean ± standard deviation [SD], number of replicates [n] = 3) at various time points.
[0045] Fig. 14 is a TREE.spot view of KIMONE.scan selectivity panel for LCI133 at 1.0 μM.
[0046] Fig. 15 is an in vivo plasma concentration profile for LCI133. Panel A: plasma concentration and time profile of LCI133-HC1 following intravenous administration of LCI133- HC1 (2 mg / kg). Panel B: plasma concentration and time profile of LCI133-HC1 and LCI133 free base after oral administration of 20 mg / kg.
[0047] Fig. 16 presents data for LCI130-series chemotypes and appropriate single agent controls screened against a panel of human endometrial carcinoma (EC) cell lines of mixed demographic, mutational, and The Cancer Genome Atlas (TCGA) classificatin backgrounds by 48-hour IC50 viability assay (panel A, all values in nanomolar (nm), - indicates an indeterminable IC50 value not reached in this 0.001-10.0 μM screen). Potency against PTEN-mutant EC cells was further explored using representative cell line AN3 CA by flow cytometry assessment of Annexin V / 7- AAD apoptosis (panel B) and Vybrant Dye Violet cell cycle (panel C) following 24-hour treatment. Western blot analysis of CDK4 / 6 signaling target Rb and CDK9 signaling and transcriptional targets RPB1 and MCL-1, and apoptosis biomarker cPARP in AN3 CA cells treated with the indicated compounds for 24-hours (panel D). qRT-PCR time-course analysis of MCL1 expression in AN3 CA cells assessed at the indicated timepoints following treatment with the indicated compounds following indicated drug treatment (panel E). Western blot analysis of PI3K- Akt signaling inhibition in AN3 CA by PI3Kα optimized chemotype LCI139 following 24-hourtreatment with the indicated compounds (panel F). Data represent the mean value or representative results (WB) from ≥2 independent experiments and error bars represent ± SEM.
[0048] Fig. 17 presents data demonstrating LCI139 simultaneously inhibits the PI3K-CDK4 / 6 signaling. Western blot analysis of lysates from IgM-stimulated JeKo-1 (panel A) and Mino cells (panel B) treated with AZD4573 and increasing concentrations of LCI139 for 1 hr. Rbp and PI3K signaling was assessed by Rbp phosphorylated at Ser2 and AKT phosphorylated at Ser473. Panel C presents qRT-PCR analysis of MCL2 and MYC expression levels in JeKo-1 cells treated with DMSO, AXD4573 (25 nM), or LCI139 (500 nM) for 1 hour and 3 hours. Data represent the mean value of two independent experiments, and error bars represent ± SD from the mean value.
[0049] Fig. 18 presents LCI139 and appropriate single agent controls screened against six human NSCLC cell lines of mixed histologic, demographic, and mutational backgrounds in logarithmic concentrations by 48-hour IC50 assay (panel A). Representative IC50curves for drug-sensitive NCI-H1703 (B, top) and drug-insensitive NCI-H1781 (panel B, bottom) cell lines. Flow cytometry analysis of NCI-H1703 cells treated with the indicated compound for 24-hours and assessed by Vybrant DyeCycle Stain staining to quantify cell cycle arrest (panel C). Western blot analysis of PI3K signaling target AKT, CDK4 / 6 target Rb, and CDK9 signaling and transcriptional targets RPB1 and MCL-1, and apoptosis biomarker cPARP in NCI-H1703 cells treated with the indicated compounds for 24-hours (panel D). qRT-PCR analysis of MCL1, SLC2A1 (Glutl), LDHA, and PFKP expression in NCI-H1703 cells assessed at 3 -hours and 24-hours following indicated drug treatment (panel E). Western blot analysis of mitochondrial oxidative phosphorylation (OXPHOS) enzyme complexes I-V, glycolysis enzymes (Glutl, PFKP, and LDHA), and mitophagy markers (Optineurin, NDP52, and LC3B-I / IIin) in NCI-H1703 cells treated with the indicated compounds for 24-hours (panel F). LCI139 (0.25pM) treatment of NCI- H1703 cells also induced time-dependent phosphorylation of the ATP stress sensor AMPK (not shown). Data represent the mean value or representative results (WB) from ≥2 independent experiments and error bars represent ± SEM. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P < 0.0001, and **** = p ≤ 0.0001 as determined by Student’s T test (GraphPad Prism).
[0050] Fig. 19 shows that LCI132 inhibits tumor growth with minimal toxicity in the immunocompetent A20 mouse model of lymphoma. Murine A20 B cell lymphoma (BCL) cells were injected into Balb / c mice and grown to 100 mm3. Once tumors reached appropriate size, animals were randomized and treated IP with vehicle control or LCI132 (40 mg / kg) QD for 17 days. All animals were monitored for tumor growth (panel A) and weight (panel C) according to approved IACUC protocol during the full course of study. At humane endpoint, all animals were sacrificed according to approved IACUC protocol, and final A20 tumor growth assessed by tumorvolume (panel B) and mass (panel D). Data represent the mean value of a single cohort of n = 7 mice (vehicle) and n= 8 mice (LCI132) and error bars represent ± SEM. ** = P < 0.01 as determined by Student’s T test (GraphPad Prism).
[0051] Fig. 20 a TREE.spot view of KIMONEscan (panel A) and BROMO.scan (panel B) selectivity profiles for LCI40 at 1.0 pM. The size of the circle represents affinity of the drug or specific protein relative to on target potency.DETAILED DESCRIPTION
[0052] The disclosures of all patent references cited herein are hereby incorporated by reference to the extent they are consistent with the disclosure set forth herein.A. _ Definitions
[0053] As used herein in the description of the invention and the appended claims, the singular forms "a," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0054] “H” refers to a hydrogen atom. “C” refers to a carbon atom. “N” refers to a nitrogen atom. “O” refers to an oxygen atom. “S” refers to a sulfur atom. “Halo” refers to F, Cl, Br or I. The term “hydroxy,” as used herein, refers to an -OH moiety. “Br” refers to a bromine atom. “Cl” refers to a chlorine atom. “I” refers to an iodine atom. “F” refers to a fluorine atom. The term “cyano” or “nitrile” refers to a -CN moiety (i.e., -C=N).
[0055] An “acyl” is intended to mean a group -C(O)-R, where R is a suitable substituent, such as alkyl, cycloalkyl, heterocycle, aryl, or heteroaryl. Examples of acyl include, but are not limited to, an acetyl group, a propionyl group, a butyroyl group, a benzoyl group, etc.
[0056] “Alkyl,” as used herein, refers to a straight or branched chain hydrocarbon containing from 1 or 2 to 10 or 20 or more carbon atoms (e.g., C2, C3, C4, C5, C6, C7, C8, C9, CIO, Cl l, C12, C13, C14, C15, etc.). In some embodiments the alkyl may be a lower alkyl. "Lower alkyl" refers to a straight or branched chain alkyl having from 1 to 3, or from 1 to 5, or from 1 to 8 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3- methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like. In some embodiments, alkyl groups as described herein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide,carbonyl, or carboxy. Representative examples of halo substituted alkyls include, but are not limited to, fluoromethyl, difluoromethyl and trifluoromethyl.
[0057] As generally understood by those of ordinary skill in the art, “saturation” refers to the state in which all available valence bonds of an atom (e.g., carbon) are attached to other atoms. Similarly, “unsaturation” refers to the state in which not all the available valence bonds are attached to other atoms; in such compounds the extra bonds usually take the form of double or triple bonds (usually with carbon). For example, a carbon chain is “saturated” when there are no double or triple bonds present along the chain or directly connected to the chain (e.g., a carbonyl), and is “unsaturated” when at least one double or triple bond is present along the chain or directly connected to the chain (e.g., a carbonyl). Further, the presence or absence of a substituent depending upon chain saturation will be understood by those of ordinary skill in the art to depend upon the valence requirement of the atom or atoms to which the substituent binds (e.g., carbon).
[0058] The term “optionally substituted” indicates that the specified group is either unsubstituted or substituted by one or more suitable substituents. A “substituent” that is “substituted” is an atom or group which takes the place of a hydrogen atom on the parent chain or cycle of an organic molecule, for example, halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide, carbonyl, or carboxy.
[0059] “Alkenyl,” as used herein, refers to a straight or branched chain hydrocarbon containing from 1 or 2 to 10 or 20 or more carbons, and containing at least one carbon-carbon double bond, formed structurally, for example, by the replacement of two hydrogens. Representative examples of “alkenyl” include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l -heptenyl, 3-decenyl and the like. In some embodiments, alkenyl groups as described herein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfide, sulfone, sulfoxide, carbonyl, or carboxy.
[0060] “Alkynyl,” as used herein, refers to a straight or branched chain hydrocarbon group containing from 1 or 2 to 10 or 20 or more carbon atoms, and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1- propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, 1-butynyl and the like. In some embodiments, alkynyl groups as described herein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide, carbonyl, or carboxy.
[0061] The term “cycloalkyl,” as used herein, refers to a saturated cyclic hydrocarbon group containing from 3 to 8 carbons or more. Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In some embodiments, cycloalkyl groups as described herein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide, or carboxy.
[0062] “Heterocycle,” as used herein, refers to a monocyclic, bicyclic or tricyclic ring system. Monocyclic heterocycle ring systems are exemplified by any 4-, 5-, 6- or 7-member ring containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of: O, N, and S. The 4-member ring has 0 to 1 double bond, the 5-member ring has from 0 to 2 double bonds, and the 6 and 7 member rings have from 0 to 3 double bonds. Representative examples of monocyclic ring systems include, but are not limited to, azetidine, azepine, diazepine, 1,3- dioxolane, dioxane, dithiane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazoline, isothiazolidine, isoxazole, isoxazoline, isoxazolidine, morpholine, oxadiazole, oxadiazoline, oxadiazolidine, oxazole, oxazoline, oxazolidine, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridine, pyrimidine, pyridazine, pyrrole, pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, tetrazine, tetrazole, thiadiazole, thiadiazoline, thiadiazolidine, thiazole, thiazoline, thiazolidine, thiophene, thiomorpholine, thiopyran, triazine, triazole, trithiane, and the like. Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system as defined herein. Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazole, benzothiazole, benzothiadiazole, benzothiophene, benzoxadi azole, benzoxazole, benzofuran, benzopyran, benzothiopyran, benzodioxine, 1,3-benzodioxole, cinnoline, indazole, indole, indoline, indolizine, naphthyridine, isobenzofuran, isobenzothiophene, isoindole, isoindoline, isoquinoline, phthalazine, pyranopyridine, quinoline, quinolizine, quinoxaline, quinazoline, tetrahydroisoquinoline, tetrahydroquinoline, thiopyranopyridine, and the like. In some embodiments, heterocycle groups as described herein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide, carbonyl, or carboxy.
[0063] “Aryl” as used herein refers to a ring system having one or more aromatic rings. Representative examples of aryl include, but are not limited to, azulenyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like. In some embodiments, aryl groups as describedherein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide, carbonyl, or carboxy.
[0064] “Heteroaryl” means a cyclic, aromatic hydrocarbon in which one or more carbon atoms have been replaced with heteroatoms. If the heteroaryl group contains more than one heteroatom, the heteroatoms may be the same or different. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, imidazolyl, thienyl, furyl, pyrazinyl, pyrrolyl, benzofuranyl, isobenzofuranyl, chromenyl, xanthenyl, indolyl, isoindolyl, indolizinyl, triazolyl, pyridazinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, isothiazolyl, and benzo[b]thienyl. Preferred heteroaryl groups are five- and six-membered rings and contain from one to three heteroatoms independently selected from the group consisting of: O, N, and S. The heteroaryl group, including each heteroatom, can be unsubstituted or substituted with from 1 to 4 suitable substituents, as chemically feasible. For example, the heteroatom S may be substituted with one or two oxo groups, which may be shown as =0. In some embodiments, heteroaryl groups as described herein are optionally substituted (e.g., from 1 to 3 or 4 times) with independently selected halo, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfide, sulfone, sulfoxide, carbonyl, or carboxy.
[0065] “Alkoxy,” as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and the like.
[0066] An “amino” is intended to mean the group -NH2.
[0067] An “amine” is a group -NRR', where R and R' are independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, etc. Disubstituted amines may have substituents that are bridging, i.e., form a heterocyclic ring structure that includes the amine nitrogen.
[0068] An “amide” as used herein refers to an organic functional group having a carbonyl group (C=O) linked to a nitrogen atom (N).
[0069] A “thiol” or “mercapto” refers to an -SH group.
[0070] A “sulfide” or “thioether” as used herein refers to a group -S-R, where R is a suitable substituent, such as alkyl, cycloalkyl, heterocycle, aryl, or heteroaryl.
[0071] A “sulfone” as used herein refers to a sulfonyl functional group, generally depicted as:wherein, R can be any covalently-linked atom or atoms, for example, H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, or heteroaryl.
[0072] A “sulfoxide” as used herein refers to a sulfinyl functional group, generally depicted as:wherein, R can be any covalently-linked atom or atoms, for example, H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, or heteroaryl.
[0073] “Carbonyl” is a functional group having a carbon atom double-bonded to an oxygen atom (C=O). In some embodiments, a carbonyl may be an α,β-unsaturated carbonyl, such as that of a methyl vinyl ketone, acrolein, acrylate, methacrylate, acrylamide, vinyl sulfonyl, propioloyl, but- 2-ynoyl, or (E)-4-(dimethylamino)but-2-enoyl. In some embodiments, an α,β-unsaturated carbonyl may act as a Michael acceptor (e.g., an electrophile).
[0074] “Carboxy” as used herein refers to a -COOH functional group, also written as -CO2H or -(C=O)-OH.
[0075] A “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, mal onates, succinates, suberates, sebacates, fumarates, maleates, butyne- 1,4- dioates, hexyne- 1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycollates, tartrates, methane-sulfonates, propanesulfonates, naphthalene- 1 -sulfonates, naphthal ene-2-sulfonates, and mandelates.
[0076] A “pharmaceutically acceptable hydrate” or “pharmaceutically acceptable hydrated salt” is intended to mean a pharmaceutically acceptable salt as defined herein that has one or more molecules of water included in its crystalline lattice.
[0077] “Form a ring” as used herein with respect to two substituents, e.g., R5and R6together forming a ring, refers to the two groups being linked together via one or more atoms (e.g., carbon) to form ring atoms making up a cycloalkyl, heterocyclo, aryl or heteroaryl as described herein. Rings may be part of a monocyclic, bicyclic or tricyclic moiety, each of such ring being a saturated or unsaturated member of the monocyclic, bicyclic or tricyclic moiety.
[0078] The terms “cancer” and “cancerous” are intended to mean the physiological condition typically characterized by unregulated cell growth in a portion of a multicellular organism. Often it is intended to mean a disease where the unregulated cell growth has the potential to spread and invade into multiple regions or tissues of the host organism (e.g., metastasis). A "tumor" comprises one or more cancerous cells. Examples of types of cancer include, but are note limited to, lymphoma, leukemia, melanoma, blastomas, sarcoma, myeloma, glioma, and germ cell tumor.
[0079] A “therapeutically effective” amount as used herein is an amount that provides some improvement or benefit to the subject. Alternatively stated, a “therapeutically effective” amount is an amount that will provide some alleviation, mitigation, or decrease in at least one clinical symptom in the subject (e.g., in the case of cancer, reduction in the size or malignancy of a tumor, death of the cancerous cells, or increase in survival time). Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.
[0080] By the terms “treat,” “treating,” or “treatment of,” it is intended that the severity of the subject's condition is reduced or at least partially improved or modified and that some alleviation, mitigation or decrease in at least one clinical symptom is achieved.
[0081] The terms “multi-target inhibitor” or “multi-target agent” as used herein refers to a single molecule having the ability to interact with at least two different protein targets in vitro and / or in vivo, which in some embodiments may include the ability to inhibit the activity or normal function of said targets, e.g., to inhibit binding or enzymatic activity. Multi-target inhibitors of the present invention in some embodiments may interact with two or more of the following targets: PI3K, bromodomain protein, CDK4, CDK6, and / or CDK9. In some embodiments the multi-target inhibitor is a dual inhibitor or a triple inhibitor.
[0082] The term “dual inhibitor” as used herein refers to the ability of a single molecule to interact with and / or inhibit the activity or normal function of two different target proteins or classes of target proteins, such as PI3K, bromodomain protein, and CDK (such as CDK4, CDK6, and / or CDK9), which may include inhibiting enzymatic activity or the interaction of the target protein with other proteins or molecules in vivo.
[0083] The term “triple inhibitor” as used herein refers to the ability of a single molecule to interact with and / or inhibit the activity or normal function of three different target proteins or classes of target proteins, such as PI3K, bromodomain protein, and CDK (such as CDK4, CDK6, and / or CDK9), which may include inhibiting enzymatic activity or the interaction of the target proteins with other proteins or molecules in vivo.
[0084] The terms “infection” or “infectious disease” are intended to mean a disease or condition that arises due to the presence of a pathogen(s) including, for example, bacteria, viruses, fungi, prions, and the like.B. _ Active Compounds
[0085] Active compounds useful as multitarget inhibitors are set forth below. In some embodiments, active compounds include those of Formula I, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula I
[0086] In some embodiments of Formula I, R1is an aryl, heteroaryl, or heterocycle; R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; and X1and X2are each independently selected from the group consisting of C and N.
[0087] For example, R1may be a group:, wherein Y is O or NH. In some embodiments, Y is O. In some embodiments, Y is NH.
[0088] For example, R1may be a group:, wherein Ra, Rb, and Rc are each independently selected from the group consisting of H, halo (e.g., Cl), hydroxy, and alkoxy.
[0089] For example, R3may be a group:wherein R4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); X3and X4 are each independently selected from the group consisting of C and N; R' is selected from the group consisting of H, alkyl, carbonyl, and alkenyl; and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl.
[0090] For example, R3may be a group:whereinR4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); X3and X4 are each independently selected from the group consisting of C and N; and R' is selected from the group consisting of H, alkyl, carbonyl, alkenyl.
[0091] For example, R3may be a group:, whereinR4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., fluroro or trifluoromethyl); X3and X4 are each independently selected from the group consisting of C and N; and R5is selected from the group consisting of H, alkyl (e.g., methyl), hydroxy, and alkoxy (e.g., methoxy).
[0092] For example, R3may be a group:, wherein R' is selected from the group consisting of H, alkyl, carbonyl, and alkenyl; and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl.
[0093] For example, R3may be a group:, wherein R' is selected from the group consisting of H, alkyl, carbonyl, and alkenyl.
[0094]
[0095] For example, R3may be a group:the group consisting of H, alkyl, carbonyl, and alkenyl; and two of R5, R6, and R7are H or alkyl, and the third is a heterocycle.
[0096] For example, R3may be a group:wherein R' is selected from the group consisting of H, alkyl, carbonyl, and alkenyl; and R8, R9, and R10are each independently H, alkyl, halo, or haloalkyl.
[0097] In some embodiments of Formula I, R' is a carbonyl. Such carbonyl may be an α,β- unsaturated carbonyl that acts as a Michael acceptor (e.g., an electrophile). Example α,β- unsaturated carbonyls include, but are not limited to those shown below.
[0098] One example compound of Formula l is a compound of Formula IA, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula IA
[0099] In some embodiments of Formula IA, R1is an aryl, heteroaryl, or heterocycle; R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; and Xi and X2are each independently selected from the group consisting of C and N.
[0100] One example compound of Formula IA, in which R1is heterocycle, is a compound of Formula IA(a), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula IA(a)
[0101] In some embodiments of Formula IA(a), Y is selected from the group consisting of O and NH; R2is H, alkyl, or hydroxy; X2and X3are each independently selected from the group consisting of C and N; R4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl.
[0102] One example compound of Formula IA(a), in which R5and R6join to form a heterocycle, is a compound of Formula IA(a)(i), or a pharmaceutically acceptable salt, hydrate, or hydrated saltFormula IA(a)(i)
[0103] In some embodiments of Formula IA(a)(i), Y is selected from the group consisting of O and NH; X2is selected from the group consisting of C and N; R2is H or hydroxy; R4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); and X3is selected from the group consisting of C and N.
[0104] Example compounds of Formula IA(a)(i) are shown below.
[0105] One example compound of Formula IA, in which R1is a heterocycle, is a compound of Formula IA(b), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula IA(b)
[0106] In some embodiments of Formula IA(b), R2is H, alkyl, or hydroxy; X1and X3are each independently selected from the group consisting of C and N; Y is selected from the group consisting of O and NH; R4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl.
[0107] One example compound of Formula IA(b), in which R5and R6join to form a heterocycle, is a compound of Formula IA(b)(i), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula IA(b)(i)
[0108] In some embodiments of Formula IA(b)(i), Y is selected from the group consisting of O and NH; R2is H or hydroxy; X3is selected from the group consisting of C and N; and R4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluorom ethyl).
[0109] Example compounds of Formula IA(b)(i) are shown below.
[0110] One example compound of Formula IA(b), in which R6and R7join to form a heterocycle, is a compound of Formula IA(b)(ii), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0111] In some embodiments of Formula IA(b)(ii), X1is N and R2is absent, or X1is C and R2isH or hydroxy; X3is C or N; and Y is selected from the group consisting of O and NH.
[0112] Example compounds of Formula IA(b)(ii) are shown below.
[0113] One example compound of Formula IA, in which R1is a heterocycle and R3is an amine, is a compound of Formula IA(c), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula IA(c)In some embodiments of Formula IA(c), Y is selected from the group consisting of O and NH;R2is H or hydroxy; Xi is selected from the group consisting of C and N; (i) two of R4, R5, and R6join to form a heterocycle, and the third is H; or (ii) two of R5, R6, and R7are H or alkyl, and the third is a heterocycle; and R7is selected from the group consisting of H, alkyl, carbonyl, and alkenyl.
[0114] In some embodiments of Formula IA(c), R7is a carbonyl. As noted above, such carbonyl may be an a,P-unsaturated carbonyl that acts as a Michael acceptor (e.g., an electrophile). Example α,β-unsaturated carbonyls include, but are not limited to those shown below.
[0115] Example compounds of Formula IA(c) are shown below.
[0116] One example compound of Formula IA, in which R1is aryl and R3is an amine, is a compound of Formula IA(d), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.Formula IA(d)
[0117] In some embodiments of Formula IA(d), Xi is selected from the group consisting of C and N; R2is H or hydroxy; R4, R5, and R6are independently selected from the group consisting of H, halo (e.g., Cl), hydroxy, and alkoxy; and two of R7, R8, and R9 join to form a heterocycle, and the third is H or alkyl.
[0118] Example compounds of Formula IA(d) are shown below.
[0119] One example compound of Formula l is a compound of Formula IB, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0120] In some embodiments of Formula IB, R1an aryl, heteroaryl, or heterocycle; R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; and Xi is selected from the group consisting of C and N.
[0121] One example compound of Formula IB, in which R1is a heterocycle and R3is aryl, is a compound of Formula IB(a), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0122] In some embodiments of Formula IB(a), Y is selected from the group consisting of O and NH; R2is H, alkyl, or hydroxy; and two of R4, R5, and R6join to form an aryl, heteroaryl or heterocycle, and the third is H or alkyl.
[0123] One example compound of Formula IB(a) is shown below.
[0124] One example compound of Formula IB(a) is a compound of Formula IB(a)(i), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0125] In some embodiments of Formula IB(a)(i), Y is selected from the group consisting of O and NH; R2is H, alkyl, or hydroxy; R7is selected from the group consisting of H, alkyl, alkoxy, cyano, amino and amide; and X3and X4 are each independently selected from the group consisting of C and N.
[0126] Example compounds of Formula IB(a)(i) are shown below.
[0127] One example compound of Formula IB, in which R1is a heterocycle and R3is heteroaryl, is a compound of Formula IB(b), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0128] In some embodiments of Formula IB(b), R2is H, alkyl, or hydroxy; R4is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; R5and R6are each independently selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl(e.g., trifluoromethyl); X2and X3are each independently selected from the group consisting of C and N; when X2is N, R5is absent; and Y is selected from the group consisting of O and NH.
[0129] One example compound of Formula IB(b) is a compound of Formula IB(b)(i), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0130] In some embodiments of Formula IB(b)(i), R2is H, alkyl, or hydroxy; Y is selected from the group consisting of O andNH; R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); X2is selected from the group consisting of C and N; when X2is N, R5is absent; and one of R7and R8is H or alkyl, and the other is selected from the group consisting of cycloalkyl, heterocycle, aryl, and heteroaryl.
[0131] One example compound of Formula IB(b)(i), in which R8is heterocycle, is a compound of Formula IB(b)(i)(x), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0132] In some embodiments of Formula IB(b)(i)(x), R2is H, alkyl, or hydroxy; Y is selected from the group consisting of O and NH; R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); X2is selected from the group consisting of Cand N; when X2is N, R5is absent; and two of R9, R10, and R11join to form a heterocycle, and the third is H or alkyl.
[0133] One example compound of Formula IB(b)(i)(x), in which R9 and Rio join to form a heterocycle, is a compound of Formula IB(b)(i)(x)(a), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0134] In some embodiments of Formula IB(b)(i)(x)(a), R2is H, alkyl, or hydroxy; R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); X2is selected from the group consisting of C and N; when X2is N, R5is absent; and Y is selected from the group consisting of O and NH.
[0135] Example compounds for Formula IB(b)(i)(x)(a) are shown below.
[0136] One example compound of Formula IB(b) is a compound of Formula IB(b)(ii), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0137] In some embodiments of Formula IB(b)(ii), R2is H, alkyl, or hydroxy; R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); X2and X3are each independently selected from the group consisting of C and N; Y is selected from the group consisting of O and NH; and one of R7and R8is H or alkyl, and the other is selected from the group consisting of cycloalkyl, heterocycle, aryl, and heteroaryl.
[0138] One example compound of Formula IB(b)(ii), in which R8is heterocycle, is a compound of Formula IB(b)(ii)(x), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0139] In some embodiments of Formula IB(b)(ii)(x), R2is H, alkyl, or hydroxy; X2and X3are each independently selected from the group consisting of C and N; Y is selected from the group consisting of O and NH; R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); and two of R9, R10, and R11join to form a heterocycle, and the third is H or alkyl.
[0140] One example compound of Formula IB(b)(ii)(x), in which in which R9 and Rio join to form a heterocycle, is a compound of Formula IB(b)(ii)(x)(a), or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0141] In some embodiments of Formula IB(b)(ii)(x)(a), R2is H, alkyl, or hydroxy; X2and X3are each independently selected from the group consisting of C and N; Y is selected from the group consisting of O and NH; and R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl).
[0142] Example compounds of Formula IB(b)(ii)(x)(a) are shown below.
[0143] Further example compounds of Formula IB are shown below.
[0144] One example compound of Formula l is a compound of Formula IC, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof.
[0145] In some embodiments of Formula IC, R1is an aryl, heteroaryl, or heterocycle; R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; and Xi is selected from the group consisting of C and N.
[0146] One example compound of Formula IC is shown below.
[0147] Any of the above formulas and compounds may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl). Non-limiting examples of such compounds are provided below, encompassed by the general Formula lx:whererin R1, R2, R3, Xi and X2are as defined above for Formula I; and Rx is halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).C. Methods of Use
[0148] In one aspect, the current invention is directed to a method for treating cancer in a subject. In some embodiments, the method comprises administering a therapeutically effective amount of a compound of the current invention to a subject in need thereof, thereby treating a cancer. In some embodiments, the cancer is lymphoma, a leukemia, a melanoma, a blastoma, a sarcoma, a myeloma, a glioma, and / or a germ cell tumor. In some embodiments, the cancer is adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia / lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexuspapilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangio sarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, nonsmall cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer,thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom macroglobulinemia, Warthin's tumor, and Wilms' tumor. See also U.S. Patent No. 11,472,814 and US 2021 / 0300939, US 2017 / 0334925 to Morales et al.
[0149] In some embodiments, the method of treating cancer in a subject further includes administering an anti-cancer therapeutic (e.g., a chemotherapeutic and / or an immunotherapeutic) to the subject. Example anti-cancer therapeutics include, but are not limited to monoclonal antibodies, T-cell transfers, vaccines, alkylating agents (e.g., carboplatin, cisplatin, oxaliplatin, dacarbazine, procarbazine, temozolamide, bendamustine, cyclophosphamide, and ifosfamide), antimetabolites (e.g., azacitidine, decitabine, cytarabine, gemcitabine, methotrexate, pemetrexed, cladribine, clofarabine, nelarabine, fluorouracil, and capecitabine), antimicrotubular agents (e.g., doxorubicin, daunorubicin, idarubicin, mitoxantrone, irinotecan, topotecan, paclitaxel, docetaxel, cabazitaxel, vinblastine, vincristine, and vinorelbine), and antibiotics (e.g., actinomycin D, bleomycin, and daunomycin). An anti-cancer therapeutic may administered sequentially and / or concurrently with a compound of the present invention.
[0150] In some embodiments, a compound of the present invention may be administered to a subject that will undergo, is undergoing, or has undergone radiation therapy, optionally where the radiation therapy is for treating a cancer.
[0151] In another aspect, the current invention is directed to a method for treating disease in a subject. In some embodiments, the method comprises administering a therapeutically effective amount of a compound of the current invention to a subject in need thereof, thereby treating disease. In some embodiments, the disease is associated with aberrant CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein activity. In some embodiments, administering compound of the present invention inhibits at least one of the CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein, thereby attenuating the at least one of the CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein aberrant protein activity. In some embodiments, the compound of the present invention may bind to the at least one of the CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein, thereby inhibiting the protein activity. In some embodiments, the compound of the present invention may covalently link to the at least one of the CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein, thereby inhibiting the protein activity. In some embodiments, the disease is non-cancer proliferative disease, sepsis, autoimmune disease, infection, atherosclerosis, Type I or 2 diabetes, obesity, inflammatory disease, fibrotic disease, neurodegenerative disease, organ systemdegenerative disease, aberrant transcriptome / epigenetic disease, and / or a metabolic or Myc- dependent disorder.
[0152] In some embodiments, the disease is a non-cancer proliferative disease, such as meningioma, cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, multiple endocrine neoplasia, nasal polyps, pituitary tumors, juvenile polyposis syndrome, prolactinoma, pseudotumor benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, vocal cord nodules, polyps, and cysts, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, and / or Castleman disease.
[0153] In some embodiments, the disease is an inflammatory disease, such as appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, psoriasis, allergy, Crohn's disease, irritable bowel syndrome, ulcerative colitis, inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, autoimmune polyglandular disease / syndrome, autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, hepatitis, gastritis, enteritis, dermatitis, gingivitis, Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, Type I diabetes, septic shock, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Graves' disease, Guillain-Barre syndrome, Behcet's disease, scleroderma, mycosis fungoides, graft versus host disease, irritable bowel syndrome, psoriasis, acute respiratory distress syndrome and / or ischemia / reperfusion injury.
[0154] In some embodiments, the disease is caused by an infection, such as a viral infection. In some embodiments, the viral infection is coronavirus infection (e.g., COVID-19), herpesvirus infection, adenovirus infection, Epstein-Barr virus infection, Ebola virus infection, human papilloma virus infection, cytomegalovirus infection, influenza virus infection, respiratory syncytial virus infection, rhinovirus infection, hepatovirus infection (e.g., hepatovirus A, hepatovirus B, hepatovirus C, hepatovirus D, and / or hepatovirus E), West Nile virus infection, alphavirus infection, and / or human immunodeficiency virus infection.
[0155] In particular embodiments, more than one administration (e.g., two, three, four or more administrations) may be employed to achieve the desired level of effective treatment over a period of various intervals, e.g., daily, weekly, monthly, yearly, etc.
[0156] In particular embodiments, administration can be local or systemic. For example, delivery of compounds encompasses situations in which a compound is delivered to a target tissue and the target protein is affected within the target tissue (also referred to as “local distribution” or “local delivery”), and situations in which a compound is delivered to into the patient's circulation system (e.g., serum) and systematically distributed and taken up by other tissues (also referred to as “systemic distribution” or “systemic delivery) where the target protein is affected. The delivery can be to any tissue affected by cancer such as the lymph nodes. Example administration methods include, but are not limited to, oral, parenteral, sublingual, transdermal, rectal, transmucosal, topical, pulmonary, nasal, or buccal. Parenteral administration includes but is not limited to intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, and intraarticular injections. Compounds or compositions of the invention may also be administered via slow controlled i.v. infusion or by release from an implant device.
[0157] Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Alternatively, one may administer the compound of the invention in a local manner, for example, in a depot or sustained-release formulation.
[0158] The present invention is explained in greater detail in the following non-limiting examples.EXAMPLESExample 1: Design and synthesis of triple CDK4 / 6-PI3K-BRD4 inhibitors.
[0159] We designed in silico and synthesized multidimensional small molecule chemotypes, dual kinases (CDK and PI3K) and an epigenetic reader domain (BRD4) to stimulate synthetic lethality in ibrutinib-resistant MCL.
[0160] Several heterocyclic pharmacophores / fragments are found in most drugs, which in some instances, depending on the overall structure and steric hindrance around the chemical scaffold, may undergo biotransformation to create toxic materials. Heterocyclic rings of possible concern include thiophene, furan, indole, benzimidazole, and benzoxazole (Gramec, D. et al., Chem. Res. Toxicol. 2014; Chen, W. et al., Chem. Res. Toxicol. 2011). Some drugs containing a thiophene, such as tienilic acid, suprofen, ticlopidine, tenoxicam, methapyrilene and thenalidine, have either been withdrawn from market or are currently being withdrawn (Hutzler, J. M. et al., Drug Metab. Dispos. 2009; Jaladanki, C. K et al., Chem. Res. Toxicol. 2015).
[0161] Previous work from our group developed a triple inhibitory chemotype against CDK4 / 6, PI3K, and BRD4, SRX3177 based on the thiopyranone scaffold (TP), which was reported to: 1) inhibit all 3 targets at nM potency 2) display potent activity in ibrutinib- resistant MCL models and 3) provide evidence of safety and therapeutic index in vivo (Burgoyne, A. M. et al., Cell Discov. 2020). Unfortunately, we have found that the TP pharmacophore showed rapid degradation in mouse and human liver microsomes (ti / 2 = <2 min) due to oxidation of sulfur, and this may generate S-oxidation and epoxidation toxic metabolites (Park, B. K. et al., Nat. Rev. Drug Discov. 2011; Jaladanki, C. K et al., Chem. Res. Toxicol. 2015; Chen, W. et al., Chem. Res. Toxicol. 2011). In this work, we replaced the TP scaffold with a benzopyranone (BP) scaffold and engineered new triple inhibitors that may simultaneously inhibit CDK4 / 6-PI3K-BRD4 at nM potency.
[0162] A series of BP containing triple inhibitors were designed via structure-based and physicochemical-property-based strategies to improve the metabolic stability, bioavailability and aqueous solubility parameters compared to the TP based multitarget small molecule inhibitor.32The triple inhibitory chemotypes were synthesized by medicinal chemistry to combine a BP scaffold33with the FDA approved a ribociclib “warhead” (a CDK4 / 6 inhibitor). An analysis of the crystal structure of the ribociclib-CDK6 complex shows that the 2-aminopyrimidine moiety is beneficial because it binds to a hinge region of the CDK6 active site. The piperazine and pyridine groups do not interact with CDK6 protein since they extend outward into the solvent phase; therefore, structural modification is more tolerated in this region.34On the other hand, the BP scaffold, which contains the unsubstituted phenyl group, can be modified by incorporating the CDK6 pharmacophores (Fig. 1).
[0163] For our initial disease focus, we have chosen ibrutinib-resistant MCL because CDK4 / 6 and CDK9 expression is elevated in MCL and associated with poor survival. In addition, LCI132 (Table 7, S. No. 1) blocked c-MYC transcription by displacing BRD4 and promote c-MYC degradation through PI3K / AKT / GSK3β signaling, resulting in maximal induction of apoptosis in MCL. The development of a potent triple CDK-PI3K-BRD4 inhibitor will exploit an important synthetic lethality to orthogonally inhibit PI3K / AKT (to augment apoptotic sensitivity) and two dominant epigenetic chromatin regulatory proteins involved in “kinome adaptation” response to address unmet needs for diseases such as ibrutinib resistant MCL.35
[0164] Herein, we report the design, synthesis, and biological evaluation of multidimensional (CDK4 / 6 / 9-BRD4-PI3K) inhibitors useful to treat the ibrutinib resistant MCL. The LCI139 (Table 7, S. No. 33) displayed pM potency against CDK9 (IC50= 0.039 nM), CDK4 (IC50= 1.50 nM), CDK6 (IC50= 3.60 nM) and PI3Ka, (IC50 = 70 nM) in cell-free assay. The cell viability assaydemonstrates that the strong cytotoxic activity of the LCI132 and LCI133 (Table 7, S. No. 3) compounds in ibrutinib resistant JeKo-1 R and Mino R than ibrutinib (IC50 Ibrutinib, 23 and 20 pM; LCI132, 538 andl l3 nM; LCI133, 130 and 14 nM, respectively). LCI133 displayed 214-fold, and 336-fold greater potency than ibrutinib in JeKo-1 R and Mino R cell lines, respectively, whereas LCI132 exhibited 43-fold higher potency in JeKo-1 R and Mino R cell lines.Chemistry:
[0165] The synthesis of 8-bromo-2-morpholino-4H-chromen-4-one (Scheme l-4a) and 7- bromo-2-morpholino-4H-chromen-4-one (Scheme l-4b) started with the alkylation of methyl 3- bromo-2-hydroxybenzoate (Scheme 1-la) or methyl 4-bromo-2-hydroxybenzoate (Scheme 1-lb) with N-acetylmorpholine (Scheme 1-2) using strong base lithium diisopropylamide (LDA) in tetrahydrofuran (THF) to produce the diketone (Scheme 1-3). After reacting with trifluoromethanesulfonic anhydride in CH2CI2, the intermediate (Scheme 1-3) underwent intramolecular cyclization-dehydration to yield the corresponding bromo precursor Scheme l-4a and Scheme l-4b in good yields.36Suzuki cross coupling reaction of the bromo precursors (Scheme l-4a and Scheme l-4b) with (4-aminophenyl) boronic acid produced the amino compounds Scheme l-5a and Scheme l-5b in excellent yields. The amino compounds (Scheme l-5a and Scheme l-5b) were reacted with the CDK4 / 6 pharmacophore, 2-chloro-7-cyclopentyl- N, A-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (Scheme 1-6) in the presence of tris(dibenzylideneacetone)dipalladium(0), NalOBu and BINAP to yield the target compounds LCI132 and LCI133, respectively (Scheme 1).
[0166] Scheme 1 shows the synthesis of LCI132, LCI133, LCI154, and LCI155.
[0167] Reagents and conditions for Scheme 1: (a) LDA, THF, 0 °C to room temperature (rt); (b) trifluoromethanesulphonic anhydride, CH2CI2; (c) (4-aminophenyl)boronic acid, Pd(PPh3)4, Na2CO3, l,4-dioxane / H2O, 100 °C; (d) 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3- ]pyrimidine-6-carboxamide, BINAP, NalOBu, tris(dibenzylideneacetone)dipalladium(0), 1,4- dioxane / toluene 110 °C.
[0168] The central pyridine ring between benzopyranone and the meta or para positioned ribociclib warhead analogs (LCI136 [Table 7, S. No. 29], LCI137 [Table 7, S. No. 30], LCI144 [Table 7, S. No. 41], and LCI145 [Table 7, S. No. 10]) and the LCI132 meta isomer, LCI138 (Table 7, S. No. 6), were synthesized as shown in Scheme 2. Suzuki cross-coupling reaction was used to synthesize these analogs from the Scheme l-4a or Scheme l-4b with (5-aminopyri din-3 - yl)boronic acid or (3-aminophenyl)boronic acid or, 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-4-(trifluoromethyl)pyridin-2-amine followed by Buchwald-Hartwig carbon-nitrogen bond formation reaction using the same reagents and conditions as described in Scheme 1.
[0169] Scheme 2 shows the synthesis of LCI136, LCI137 (Table 7, S. No. 30), LCI138, LCI144, and LCI145.
[0170] Reagents and conditions for Scheme 2: (a) (5-aminopyridin-3-yl)boronic acid or (3- aminophenyl)boronic acid or 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyridin-2-amine, Pd(PPh3)4, Na2CO3, l,4-dioxane / H2O, 100 °C; (b) 2-chloro-7- cyclopentyl-A,A-dimethyl-7H-pyrrolo[2,3-d]pyrirnidine-6-carboxarnide, BINAP, Na'OBu, 1,4- dioxane / toluene 110 °C.
[0171] To study the role that the hydrophobic phenyl group plays on the inhibitory activity and selectivity of the three target proteins, we synthesized two analogs with no central phenyl group between the benzopyranone and CDK4 / 6 warhead as shown in Scheme 3. In addition to lowering molecular weight, the phenyl group removal is predicted to result in better cell permeability and improved ADME properties. The target compounds were synthesized using palladium catalyzed carbon-nitrogen bond formation reaction between Scheme l-4a or Scheme l-4b and Scheme 3- 14 in the presence of Cs2CO3, BINAP, in 1,4-dioxane at 100°C for 12 h.
[0172] Scheme 3 shows the synthesis of LCI139, LCI140 (Table 7, S. No. 38) , LCI156, and LCI158.
[0173] Reagents and conditions for Scheme 3: (a) Cs2CO3, Pd(OAc)2, BINAP, 1,4-dioxane, 100 °C.
[0174] To improve the aqueous solubility, metabolic stability, and oral bioavailability of the most potent triple CDK-PI3K-BRD4 (LCI132) and dual PI3K / CDK inhibitors (LCI136 and LCI139), we replaced morpholine with a piperazine ring. The synthesis of the piperazine bromo precursorScheme 4-1 la and Scheme 4-1 lb started with the same starting materials (Scheme 1-la and Scheme 1-lb) as shown in Scheme 1, and the reaction with tert-butyl 4-acetylpiperazine-l- carboxylate (Scheme 4-9) used the same reagents and conditions as described in Scheme 1. The intermediates Scheme 4-1 la or Scheme 4-1 lb were Boc protected with di-tert-butyl decarbonates (BOC)2O in the presence of N,N-diisopropylethylamine (DIPEA) in CH2CI2at room temperature. The target piperazine analogs LCI141 (Table 7, S. No. 4) and LCI142 (Table 7, S. No. 39) were synthesized by the Suzuki coupling chemistry of Scheme 4-12a or Scheme 4-12b with (4- aminophenyl)boronic acid or (5-aminopyridin-3-yl)boronic acid and Buchwald-Hartwig amination reaction with Scheme 1-6 to yield the Boc protected analogs. In the final step, the Boc group was deprotected with 30% TFA in CH2CI2 at room temperature to produce the target piperazine analogs (Scheme 4). Similarly, the LCI143 (Table 7, S. No. 40) was synthesized by Buchwald-Hartwig coupling reaction of bromine precursor Scheme 4-12b and amine Scheme 4- 1437and then Boc deprotected (Scheme 4).
[0175] Scheme 4 shows the synthesis of 2-piperazine-benzopyranone based triple inhibitors.
[0176] Reagents and conditions for Scheme 4: (a) LDA, THF, 0 °C to rt; (b) trifluoromethanesulphonic anhydride, CH2CI2; (c) (Boc)2O, DIPEA, rt; (d) (4- aminophenyl)boronic acid, Pd(PPh3)4, Na2CO3, l,4-dioxane / H2O, 100 °C; (e) 2-chloro-7- cyclopentyl-N,N -dimethyl-7H-pyrrolo[2,3-d ]pyrimidine-6-carboxamide, BINAP, NatOBu, 1,4- dioxane / toluene 110 °C or CS2CO3, Pd(OAc)2, BINAP, 1,4-dioxane; (f) TFA, CH2CI2.
[0177] The replacement of morpholine with a 4-methoxyphenyl group analogs, which were intended to improve metabolic stability, were synthesized as shown in Scheme 5. Treatment of l- (3-bromo-2-hydroxyphenyl)ethan-l-one (Scheme 5-15a) or l-(4-bromo-2-hydroxyphenyl)ethan- 1-one (Scheme 5-15b) with strong base lithium bis(trimethylsilyl)amide (LiHMDS) at -78 °C andfollowed by reaction with methyl 4-methoxybenzoate (Scheme 5-16) to yield diketones Scheme 5-17a and Scheme 5- 17b in good yields. The intermediates, Scheme 5-17a and Scheme 5-17b, underwent intramolecular cyclization and condensation in the same reaction conditions as described in Scheme 1. Bromo precursors (Scheme 5-18a and Scheme 5-18b) were then exposed to Buchwald-Hartwig conditions with 2-amino-7-cyclopentyl-A,A-dimethyl-7H-pyrrolo[2,3- d]pyrimidine-6-carboxamide to yield the target compounds LCI148 and LCI47, respectively.
[0178] Scheme 5 shows the synthesis of 2-(4-methoxyphenyl)-benzopyranone based triple inhibitors.
[0179] Reagents and conditions for Scheme 5: (a) Lithium bis(trimethylsilyl)amide(LiHMDS), THF, -78 °C to rt; (b) trifluoromethanesulphonic anhydride, CH2CI2, 0 °C to rt; (c) 2- amino-7-cyclopentyl-A,A-dimethyl-7H-pyrrolo[2,3-J]pyrimidine-6-carboxamide, BINAP, CS2CO3, Pd(OAc)2, 1,4-dioxane, 100 °C.
[0180] In-silico molecular modelling analysis indicated that the 2-aminopyrimide group exhibited bidentate interactions with the CYS106 residue, suggesting that the introduction of a Michael acceptor group at the hydrogen bond donor site may form a covalent bond with the CYS106 residue. Thus, the one CDK9 covalent inhibitor was synthesized by the reaction of LCI139 with acryloyl chloride in the presence of A,A-diisopropylethylamine in CH2CI2at room temperature (Scheme 6).
[0181] Scheme 6 shows the synthesis of a CDK9 irreversible inhibitor.
[0182] Reagents and conditions for Scheme 6: (a) acryloyl chloride, N,N- diisopropylethylamine, CH2CI2.
[0183] Two carboxylic acid analogs were synthesized as shown in Scheme 7. The introduction of a carboxylic acid group at the meta position of the central phenyl ring was hypothesized to improve the BRD4 inhibition activity through interactions with positive charge lysine residues in the protein. The bromo benzopyranones (Scheme l-4a and Scheme l-4b) intermediates were exposed to Suzuki cross coupling reaction with 3-borono-5-bromobenzoic acid and then methylation of carboxylic acid with methyl iodide to yield the corresponding esters Scheme 7-21 and Scheme 7-22 in good yields. As described in Scheme 1, Buchwald coupling reagents and conditions with 2-amino-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6- carboxamide produced methyl esters followed by hydrolysis to regenerate target acids LCI149 and LCI150.
[0184] Scheme 7 shows the synthesis of acid analogs LCI149 and LCI150.
[0185] Reagents and conditions for Scheme 7: (a) 3-borono-5-bromobenzoic acid, Pd(PPh3)4, Na2CO3, l,4-dioxane / H2O, 100 °C; (b) CH3I, K2CO3,DMF; (c) 2-amino-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, BINAP, CS2CO3, Pd(OAc)2, BINAP, 1,4- dioxane; (d) IN NaOH, THF / MeOH 60 °C.
[0186] Scheme 8 Synthesis of BP with pyrimidine-benzimidazole analogue (LCI163). Suzuki cross-coupling reaction of the 2-amino-4-chloro pyrimidine (28) and boronic esters (29) produced the amino compound (31) with excellent yields. The amino compound (31) was reacted with the 7-bromo-2-morpholino benzopyranone in the presence of CS2CO3, Pd(OAc)2 and BINAP to yield target compound LCI163 (Scheme 8).Reagents and conditions for Scheme 8: (a) Pd(PPhs)4, Na2CO3, l,4-dioxane / H2O, 100 °C; (b) BINAP, CS2CO3, Pd(OAc)2, BINAP, 1,4-dioxane, 100 °C.
[0187] Synthesis of 7-cyclopentyl-A,A-dimethyl-2-(A-(2-morpholino-4-oxo-4H-chromen-7- yl)acrylamido)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI151). To a stirred solution of LCI139 (0.1 g, 0.19 mmol) in CH2CI2(20 mL), both N A-diisopropylethylamine (100 μL, 0.59 mmol) and acryloyl chloride (47 μL, 0.59 mmol) were added. The mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with aqueous NaHCC3solution and extracted with CH2CI2(two, 50 mL extractions). The combined CH2CI2solution was dried over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. The residue was purified by flash column chromatography using CH2Cl2 / MeOH as eluent to afford the pure product as light-yellow foam.Computational Chemistry:
[0188] In silico molecular docking studies were employed to understand predicted interactions between the most active triple (CDK4 / 6 / 9-BRD4(BDl)-PI3Kδ) (LCI132) and CDK4 / 6 / 9-PI3K5 inhibitors (LCI136), and its target proteins. LCI132 was derived from the dual PI3K / BRD4 inhibitor LY294002. We developed molecular models to design and dock molecules in silico with high confidence. With a powerful small molecule drug discovery software suite (Schrodinger- 2021-3 model), we used published crystal structures of ligands in CDK6 (PDB code:5L2T), CDK9 (PDB code: 3BLR), BRD4 (PDB code: 4CFK), PI3K5 (PDB code: 5I6U), and PI3Ka (PDB code: 4JPS) in silico, removed the ligands and re-docked them, reproducing the ligands binding conformations in the published crystal structure. Using these molecular models and in silico docking we introduced the CDK6 binding pattern ribociclib (co-crystallized ligand) into our designed compounds in such a way as to inhibit three targets BRD4, PI3K5, and CDK6 / 9, thereby creating novel candidates, LCI132 and LCI136. The key binding interactions of LCI132 and target proteins are depicted in Fig. 1. The docking model for the CDK6 active site showed that the LCI132, 2-aminopyrimide moiety formed two critical hydrogen bonds with VAL101, the side chain carbonyl oxygen engaged with ASP163, and the pyrrole group provided π -stacking interactions with the PHE98 residue (Fig. 1, panel A). The docking pose in the CDK9 catalytic site shows that the LCI132, benzopyranone carbonyl forms hydrogen bonds with the hinge residue CYS106. Importantly, the amino group hydrogen bond interactions with ASP167 and pyrimide ring π -stacking with PHE30 contribute to its potent inhibitory effect on CDK9 kinase activity (Fig.1, panel B).
[0189] The LCI132, benzopyranone (BP) carbonyl interacts with conserved residue ASN140 and H2O-mediated hydrogen bond networks with TYR97 in the BRD4 BD1 acetyl-lysine binding site of BRD4 (Fig. 1, panel C). The same analog that fits well in the PI3K5 active site showed BP carbonyl hydrogen bonds with ASP911 and pyrimidine ring π -stacking interactions with the TRP760 residue (Fig. 1, panel D). Additionally, morpholino group oxygen engages hydrophobic interactions with VAL828, contributing to PI3K5 selectivity. We found that phenyl or pyridine rings attached at 7thposition of 2-morpholino BP scaffolds (LCI133 and LCI136) killed the BRD4 inhibitory activity and enhanced CDK4 / 6 / 9 activity and selectivity when compared to analogs with 8thposition phenyl or pyridine containing analog (LCI132).
[0190] The molecular model for the CDK6 active site interacting with LCI136 demonstrates additional hydrogen bond interactions with the TYR24 residue compared to LCI132, which is predicted to account for its exceptional CDK4 / 6 kinase inhibitory potency (Fig. 2, panel A). LCI136 fit well in the ATP binding site of CDK9 and shows three strong hydrogen bondinteractions with LYS48, CYS106, and GLU107 residues (Fig. 2, panel B). The docking coordinates of LCI136 in the PI3K5 active site shows that amine group engaged in an important hydrogen bonding interaction with VAL828, which contributes to PI3K5 selectivity (Fig. 2, panel C). The same analog’s pyridine nitrogen interacts with VAL851 residue in the PI3Ka active site, which is critical to PI3Ka selectivity. Additionally, LCI136 forms two hydrogen bonds with LYS802 (side chain carbonyl) and GLN859 (BP carbonyl), and π -stacking interactions with the TYR836 residue (Fig. 2, panel D).
[0191] The molecular docking results indicate that LCI132 and LCI136 fit well in the active site binding pockets of CDK6 / 9, BRD4, and PI3K5, and form strong binding interactions with the key residues in each active sites, demonstrating its potential to inhibit target proteins - CDK4 / 6 / 9, BRD4, and PI3K5 - at nM and / or pM potency.
[0192] In silico modeling of the binding interactions of LCI139 with PI3Kα and CDK9 proteins.
[0193] We used published crystal structures of ligands in PI3Ka (PDBID: 4JPS) and CDK9 (PDB code:4BCF) in silico, removed the ligands, and re-docked them reproducing the ligand binding conformations in the published crystal structure. With these molecular models and in silico docking we introduced the PI3Ka binding fragment alpelisib (co-crystallized ligand) into our designed compounds in such a way as to inhibit CDK9, thereby creating novel candidates LCI139 and LCI143. The key binding interactions of LCI139 and target proteins are depicted in Fig. 3. The docking model for the PI3Ka active site showed that LCI139 engages via bidentate interactions through the pyrimidine and amine NH with the backbone atoms of VAL851, contributing to the PI3Ka selectivity, and chromone carbonyl oxygen hydrogen bond interacts with the side chain amine of GLN859, and phenyl group π -stacking interacts with TRP780 residue. Additionally, there is a strong non-covalent interaction (π -cation) between benzopyranone π electrons and the positive charged ARG770 residue (Fig. 3, panel A and Fig. 3, panel B). The same analog that fits well in the CDK9 active site, a 2-aminopyrimide moiety, interacts with the kinase hinge via a chelation type hydrogen bond with the backbone atoms of CYS106 and side chain carbonyl oxygen interacts with the LYS167 residue (Fig. 3, panel C and Fig. 3, panel D). The molecular docking results indicate that LCI139 fits well in the active site pockets of PI3Ka and CDK9 and forms strong binding interactions with the key residues in two active sites, demonstrating its potential to inhibit target proteins - PI3Ka and CDK9 - at nM or pM potency.Structure Activity Relationships (SAR):
[0194] Initially, we designed and synthesized two triple inhibitory analogs, LCI132 and LCI133, by incorporating the CDK4 / 6 warheads 7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide into 2-morpholino-8-phenyl-benzopyranone scaffold. To test the inhibitory activities of LCI132 and LCI133, a cell-free assay for the potency of three target proteins was performed. Interestingly, the LCI132 analog possessing a phenyl group in the 8thposition and the CDK4 / 6 warhead in the para position retained the PI3K-BRD4-CDK4 / 6 inhibition activities in the cell-free assay (Table 1). The LCI133 chemotype is a positional isomer of LCI132, with the phenyl group at 7thposition of the 2-morpholino BP scaffold, and showed high potency CDK4 / 6 inhibition (IC50= 4.7 / 10.2 nM) and moderate inhibition of PI3K5 (IC50= 897 nM). It was dead for BRD4 inhibitory activity. Based on these informative results, we designed and synthesized three new LCI candidates, LCI136, LCI137, and LCI138, with the CDK4 / 6 warhead in the meta position. Substitution of pyridine or phenyl at 8thposition of the BP scaffold with the CDK4 / 6 warhead at the meta position (LCI137 and LCI138) were not associated with significant activity against PI3K and BRD4 targets. Synthesis of an analog with the pyridine at 7thposition of BP scaffold and the CDK4 / 6 warhead at the meta position (LCI 136) resulted in exceptional potency against PI3K and CDK4 / 6 targets (Table 1). The analog LCI139 without hydrophobic phenyl group between the ribociclib (Ribo) warhead and the BP scaffold shows excellent activity towards PI3Kα (IC50= 70.2 nM) and CDK4 / 6 (IC50 = 1.5 / 3.6 nM), but was dead for BRD4 inhibitory activity. The piperazine containing analog (LCI142) exhibited nM activity against CDK4 / 6 / 9 (IC50 = 7.5 / 17 / 2 nM) and PI3Kδ (IC50= 542 nM) but did not show activity against BRD4 target. These results suggest that phenyl and morpholine groups around the BP scaffold play an essential role in balancing the activity towards the three targets. The LCI132 is a nanomolar inhibitor of CDK4 / 6 / 9- PI3K-BRD4, whereas LCI133, LCI 136, and LCI139 show picomolar potency against CDK9 (IC50 = 430, 570, 39 pM, respectively) with single digit nanomolar potency against CDK4 / 6 (Table 1). It is important to add that CDK9 has increasingly become a target of interest in cancer therapeutics. CDK9 is a serine / threonine protein kinase that activates RNA polymerase II to promote cellular transcription and proliferation, and reduction of CDK9 has been implicated in the inhibition of the PI3K / AKT signaling pathway.38LCI 132, LCI133, LCI136, and LCI139 compounds were displayed a nanomolar activity against AURKA / B (Table 2). Aurora kinase A and B (AURKA / B) is another serine / threonine kinase cell cycle / mitosis regulator has been associated with clinical aggressiveness, poor prognosis and survival, and therapeutic resistance in hematological malignancies and solid tumors.
[0195] Table 1 : In vitro cell free data for PI3K / BRD4 / CDK4 / 6 triple inhibitory chemotypes (nM):
[0196] Table 2. Selected compounds activity against AURKA / B, DNAPK, and PI3KP (nM).
[0197] Table 3 : In vitro cell free data for selected compounds CDK profiles:
[0198] Table 4 : In vitro cell free data for PI3K / BRD4 dual inhibitory chemotypes (nM):The anti-proliferative effect of triple inhibitors LCI132, and LCI133 in MCL cell lines.
[0199] Importantly, LCI132 was less toxic to healthy donor B-cells and HS-5 stromal cells when compared to the combination of single target drugs (PLX51107+BKM-120+Ribo) required to effectively inhibit the same three targets (Fig. 6, panel A and Fig. 6, panel B). To compare the inhibitory profiles of the LCI132, LC133, PLX51107 (a BET inhibitor), ribociclib (a CDK4 / 6 inhibitor), ibrutinib (a BTK inhibitor), BKM-120 (a pan PI3K inhibitor), and LCI28 (a dual PI3K / BRD4 inhibitor), we performed cytotoxicity experiments in JeKo-1 and Mino cells, a human MCL cell line, with increasing concentrations of LCI132, LC133, PLX51107, ribociclib, ibrutinib, BKM-120, and LCI28. The dose response curves generated from CellTiter-Glo cell viability assays demonstrated strong cytotoxic activity of LCI132 and LCI133 compounds (Fig. 6, panel C and Fig. 6, panel D). Compared to ibrutinib, LCI132 and LCI133 analogs had 16-fold and 33-fold greater potency in JeKo-1 cells, and 5-fold and 9-fold greater potency in Mino cells.LCI132 and LCI133 impair PI3K / Rb / c-MYC signaling induce apoptosis and arrest cell cycle.
[0200] The effect of LCI132 and LCI133 on activation of PI3K / CDK4 / 6 and c-MYC signaling was examined in IgM stimulated JeKo-1 and Mino parental MCL cells using western blot analysis. In cells treated with LCI132 and LCI133, pAKT (S473) (a downstream effector of PI3K), pRb (S780), and c-MYC expression was blocked simultaneously, whereas single target reference drugs (ribociclib, BKM-120, and PLX51107) inhibited the specific targets. The result strongly suggests that LCI triple inhibitors can simultaneously inhibit all three targeted pathways at the same time in the same cell. This is the definition of synthetic lethality. Importantly, we hypothesize that the administration of single inhibitors against three different targets in vivo will not likely inhibit all three targets in the same cell at the same time. (Fig. 9, panel A and Fig. 9, panel B). In addition, LCI132 efficiently blocked the cell cycle in G1 phase (60.6 %) as compared to the DMSO control (40.9%) (Fig. 9, panel C). To examining the durability of the triple inhibitor in context to prolonged G1 arrest, we treated the MCL cells with 500 nM of LCI132 and DMSO control for 4, 8, 12, 24, 48 and 72h (Fig. 9, panel D). We observed that LCI132 significantly induced prolongedG1 arrest correlated with sustained inhibition of pRb phosphorylation. Given the synergy between CDK4 / 6i and PI3Ki in MCL23, we performed apoptosis assays by treating JeKo-1 cells with LCI132, LCI133, or single target inhibitors. These data demonstrate that concurrent inhibition of all three targets with LCI132 and LCI133 in the same cell and at the same time induced significant apoptotic cell death in JeKo-1 and Mino cells compared to single agent target inhibition (Fig. 9, panel E and Fig. 9, panel F).LCI132 and LCI133 overcomes ibrutinib resistance in MCL.
[0201] To investigate the potency of LCI triple inhibitors in overcoming ibrutinib resistance, we performed cell viability experiments in ibrutinib-resistant JeKo-1 R and Mino-R cells, with increasing concentrations of ibrutinib, LCI133, LC132, LCI28, BKM-120, ribociclib, ribociclib+BKM-120, and riboci clib+ibrutinib. The dose response curves generated from CellTiter-Glo cell viability assays demonstrated strong cytotoxic activity of LCI132 and LCI133 compounds against ibrutinib-resistant MCL cells in vitro (Fig. 10, panel A and Fig. 10, panel B). LCI133 displayed 214-fold, and 336-fold greater potency than ibrutinib in JeKo-1 R and Mino R cell lines, respectively, whereas LCI132 exhibited 43-fold higher potency in JeKo-1 R and Mino R cell lines. LCI132 and LCI133 induced apoptosis and G1 cell cycle arrest in JeKo-1 R cells compared to single target agents (Fig. 10, panel C and Fig. 10, panel D). LCI133 is a highly potent CDK4 / 6 / 9 and moderate PI3Kδ inhibitor with no BRD4 inhibitory activity, however, it shows potent synergistic activity against ibrutinib-resistant MCL tumor cells. In MCL cells and ibrutinib-resistant MCL cells, LCI132 and LCI133 showed improved activity. In addition, LCI133 exhibited higher potency than the combination of two drugs (Ribo + BKM-120, or Ribo + ibrutinib) in JeKo-1 Rcell lines. These data suggest that LCI 132 or LCI 133 can overcome ibrutinib resistance through the concomitant inhibition of CDK4 / 6, BRD4, and PI3K5 as synthetic lethality partners.
[0202] Table 5 : In vitro cellular IC50(nM) values in human MCL cell linesIn-vitro pharmacokinetic (PK) properties:
[0203] The in vitro ADME properties of triple PI3K-BRD4-CDK4 / 6 inhibitors LCI132 and LCI136 were determined by measuring their kinetic solubility, microsomal stability (in human liver microsome [HLM] and mouse liver microsome [MLM]), intrinsic clearance (CLint), hepatic intrinsic clearance (CLint H), and mouse plasma protein binding stability by using an LC-MS / MS Shimadzu Nexera UPLC system. The LCI132 and LCI136 exhibited >90% drug remaining after 2 h incubation in simulated gastric fluid (SGF) at pH 1.2 and in simulated intestinal fluid (SIF) at pH 6.8 and PBS at pH7.4. The LCH36 had a longer half-life in HLM, as well as favorable kinetic solubility, intrinsic clearance, and plasma protein stability (Table 6).
[0204] Table 6: In vitro PK parameters for LCI132 and LCI136.
[0205] The predicted molecular properties of selected compounds and recommended range (Table 7) were calculated using Schrodinger software 2022-3 version QikProp panel. The LCI139 have shown better physicochemical parameters than the other LCI candidates.Table 7. Predicted physicochemical properties for selected compounds.
[0206] LCI133 kinome selectivity profiles:
[0207] One of the most challenging aspects in cancer research is the selectivity or lack thereof of kinase inhibitor drugs. Several clinical trials have failed because of off-target inhibitor toxicity due to structurally similar kinase drug pockets. The drug pockets of human kinases are highly similar,but they are not identical. We determined the selectivity profile of LCI133 using the scanMAX kinome-wide selectivity assay (at 1.0 pM) against 468 (403 non-mutant kinases, 65 mutant kinases) kinases show that LCI133 is highly selective for these AURKA-CDK4 / 9 targets (Fig. 14). The percentage of controls for AURKA, CDK4-cyclinDl, and CDK9 is 0, 2.6, and 3.9, respectively. Kinases that bind were marked with red circles if <35% of the respective recombinant kinase were captured on the immobilized ligand in the presence of the indicated concentration of LCI133, normalized to a DMSO control. Larger circles represent a higher affinity of binding. The standard selectivity score, S(x), is shown in Table 8 by using three different thresholds. The S- score represents the fraction of kinases inhibited at a particular level. The S(35), S(10), and S(l) selectivity scores of LCI133 were 0.057, 0.015, and 0.002, respectively. These data indicate that LCI133 potently inhibits CDK9-CDK4 / 6- AURKA whereas retaining a high level of kinase panel selectivity. Inhibitory IC50concentrations are then determined by a dose response titration for LCI133 against each specific target identified in the screen. LCI152 was designed by the replacement of morpholine with a piperazine at the 2nd position to the BP scaffold. It exhibited nM potency against CDK9, CDK4 / 6, and AURKA / B (IC50= 6.2, 4.5 / 4.9, and 11.2 / 34.7 nM, respectively). Importantly, compared to FDA approved kinase inhibitors, LCI133 S(35) is 2-11 fold more selective against their designed specific targets than: 1) gefitinib, 2) imatinib, 3) erlotinib, 4) sorafenib, 5) dasatinib, and, 6) sunitinib.
[0208] Table 8 LCI133 KINOMEscan selectivity scores.
[0209] In vivo pharmacokinetic properties for LCI13: Pharmacokinetic and pharmacodynamic relationships are one of the hallmarks of successful drug discovery and development. A clear understanding of how much plasma exposure of drug leads to clear target engagement in the tissue of interest and relating that to the observed outcomes in an in vivo assay, is crucial for translating animal efficacy into human clinical development. Given the favorable potency and selectivity of LCI133, we performed in vitro stability, in vivo mouse pharmacokinetic studies. We tested LCI133 free base and LCI133-HC1 salt forms of drugs in mouse PK at an intravenous dose (IV) of 2 mg / kg (Fig. 15, panel A) and oral dose of 20 mg / Kg (Fig. 15, panel B). LCI133-HC1 salt form of the drug in vivo PK data demonstrate that favorable systemicexposure (AUC0-∞ ) of 7812 ng X h / mL and maximum plasma concentration of 3305 ng / mL, which leads to an oral bioavailability of 29% (Table 9). After oral administration of 20 mg / kg dose of LCI133-HC1 to Balb / c mice, LCI133-HC1 was distributed in tissues with the following order: liver>kidney> spleen> brain>lungs. As a result of 24 hours of exposure, a higher concentration of drug was found in the kidney (30 ng / g), liver (14 ng / g), lungs (7 ng / g), and brain (5.5 ng / g), respectively (Table 10). Hence, LCI133 has an excellent PK / bioavailability profile.Table 9. In vivo mice PK parameters for LCI133-HCI and LCI133 free baseTable 10. Tissue distribution (ng / g) of LCI133-HCI after 20 mg / Kg oral administration
[0210] LCI133 is nanomolar potent against PTEN-PI3K co-mutated endometrial carcinoma and induce cell cycle arrest and apoptosis: LCI130-series chemotypes and appropriate single agent controls were screened against a panel of human endometrial carcinoma (EC) cell lines ofmixed demographic, mutational, and The Cancer Genome Atlas (TCGA) classification backgrounds by 48-hour IC50 viability assay (Fig. 16, panel A). Potency against PTEN-mutant EC cells was further explored using representative cell line AN3 CA by flow cytometry assessment of Annexin V / 7-AAD apoptosis (Fig. 16, panel B) and Vybrant Dye Violet cell cycle (Fig. 16, panel C) following 24-hour treatment. Western blot analysis of CDK4 / 6 signaling target Rb and CDK9 signaling and transcriptional targets RPB1 and MCL-1, and apoptosis biomarker cP ARP in AN3 CA cells treated with the indicated compounds for 24-hours (Fig. 16, panel D). qRT-PCR time- course analysis of MCL1 expression in AN3 CA cells assessed at the indicated timepoints following treatment with the indicated compounds following indicated drug treatment (Fig. 16, panel E). Western blot analysis of PI3K-Akt signaling inhibition in AN3 CA by PI3Ka optimized chemotype LCI139 following 24-hour treatment with the indicated compounds (Fig. 16, panel F).
[0211] LCI139 blocks expression of CDK9 and PI3K signaling in mantle cell lymphoma cell cines: To examine the effect of the multitarget inhibitor LCI139 in inhibiting the CDK9 and PI3K signaling, we treated the JeKo-1 and Mino cells with varying concentration of LCI 139 and single concentration of the control drug. The result from the western blot analysis shows that LCI139 effectively block the CDK9 downstream targets such as phospho RNA polymerase at ser 2, MCL- 1 and cMYC, and PI3K target pAKT at ser 473. Moreover, the nature of CDK9 function is to fine tune the transcription machinery. Therefore, suppressing CDK9 function by genetically or pharmacologically resulted in default transcription and impact cancer cell proliferation and growth. To establish weather LCI139 demines the anti-apoptotic protein MCL-1 and cMYC, we expose the JeKo-1 cells with LCI139 and the positive control AZD4573 for one and three hour. The q-PCR result show that LCI139 significantly suppress MCL1 and MYC transcription. All together the result shows that LCI139 simultaneously inhibit CDK9 and PI3K targets (Fig. 17) at nM potency.
[0212] LCI139 targets kinase signaling and cellular bioenergetics to induce apoptosis in non-small cell lung cancer: LCI139 and appropriate single agent controls were screened against six human NSCLC cell lines of mixed histologic, demographic, and mutational backgrounds in logarithmic concentrations by 48-hour IC50 assay (Fig. 18, panel A). Representative IC50 curves for drug-sensitive NCI-H1703 (Fig. 18, panel B, top) and drug-insensitive NCI-H1781 (Fig. 18, panel B, bottom) cell lines. Flow cytometry analysis of NCI-H1703 cells treated with the indicated compound for 24-hours and assessed by Vybrant DyeCycle Stain staining to quantify cell cycle arrest (Fig. 18, panel C). Western blot analysis of PI3K signaling target AKT, CDK4 / 6 target Rb, and CDK9 signaling and transcriptional targets RPB1 and MCL-1, and apoptosis biomarker cP ARP in NCI-H1703 cells treated with the indicated compounds for 24-hours (Fig.18, panel D). qRT-PCR analysis of MCLl, SLC2A1 (Glutl), LDHA, and PFKP expression in NCI- H1703 cells assessed at 3-hours and 24-hours following indicated drug treatment (Fig. 18, panel E). Western blot analysis of mitochondrial oxidative phosphorylation (OXPHOS) enzyme complexes I-V, glycolysis enzymes (Glutl, PFKP, and LDHA), and mitophagy markers (Optineurin, NDP52, and LC3B-I / IIin) in NCI-H1703 cells treated with the indicated compounds for 24-hours (Fig. 18, panel F). LCI139 (0.25pM) treatment of NCI-H1703 cells also induced time-dependent phosphorylation of the ATP stress sensor AMPK (not shown). Data represent the mean value or representative results (WB) from ≥2 independent experiments and error bars represent ± SEM. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P < 0.0001, and **** = P ≤ 0.0001 as determined by Student’s T test (GraphPad Prism).
[0213] LCI132 inhibits tumor growth with minimal toxicity in the immunocompetent A20 mouse model of lymphoma. Murine A20 B cell lymphoma (BCL) cells were injected into Balb / c mice and grown to 100 mm3. Once tumors reached appropriate size, animals were randomized and treated IP with vehicle control or LCI132 (40 mg / kg) QD for 17 days. At end of study, LCI132 treatment significantly decreased A20 tumor growth as measured by tumor volume and mass (Fig. 19A, 19B, 19D) Further, LCI132 treatment did not result in statistically significant weight loss; indicative of low toxicity (Fig. 19C). Together, these proof-of-concept data demonstrate that (1) formulating LCI132 for in vivo administration is feasible, (2) LCI132 exhibits in vivo antitumor activity against BCL, and (3) LCI132 treatment is nontoxic to mice.
[0214] Design and synthesis of dual PI3K / BRD4 inhibitors. Dual inhibitors (LCI28, LCI29, LCI35, LCI36, LCI40, LCI53, and LCI73) were designed via medicinal chemistry and structural optimization strategy to improve metabolic stability, bioavailability, and aqueous solubility parameters compared to LY294002; a dual PI3K-BRD4 small molecule inhibitor. Dual inhibitors were synthesized as shown in Scheme 9 using same reagents and conditions as described in the Scheme 1 and Scheme 4. LCI40 exhibited >27-fold more potent against BRD4(BD1) (IC50= 190 nM) and >7-fold more potent against PI3Kα / PI3Kδ (IC50= 71 / 71 nM) than the backbone compound LY294002 (IC50s: BRD4(BD1) = 5300 nM, PI3Kα = 500 nM, PI3Kδ = 570 nM).
[0215] Reagents and conditions for Scheme 9: (a) Pd(PPh3)4, Na2CO3, 1,4-dioxane / H2O, 100 °C
[0216] LCI40 KinomeSCAN and BromoSCAN selectivity profiles. LCI40 was evaluated in a comprehensive selectivity panel KINOMEscan against 468 kinases and BROMOscan against 31 bromodomains. Dual inhibitor LCI40 showed excellent selectivity for PI3K-family lipid kinases (Fig. 19A) and BRD4-bromodomain-l (Fig. 19B) at 1.0 μM. Kinome and bromoscan profiling assays confirmed the specificity of LCI40 and the absence of significant off-target interactions.
[0217]
[0218] The binding free energy and glide emodel score were calculated using Schrodinger 2022- 3 version software. Molecular docking was performed by following steps: (1) the targeted proteins were prepared by protein preparation wizard panel; (2) receptor grid generation using GLIDE application with default parameters; (3) ligand preparation using LigPrep panel; and (4) ligands were docked in target proteins using GLIDE Ligand Docking panel with the extra precision method (XP). The top-scoring compounds predicted to have the highest affinity towards the three targets were selected and are shown in Table 11. “Docking score” is a scoring function forpredicting the binding affinity of ligands and targets after docking; “Binding free energy” is the sum of all the intermolecular interactions that is present between the ligand and the target, more negative values represent tighter binders; “Emodel” is a significant weighting of the force field components (electrostatic and van der Waals energies), which makes it well-suited for comparing conformers, but much less so for comparing chemically-distinct species.Table 11. Top scored compound structures and their docking and glide emodel scores.CONCLUSION:
[0219] In conclusion, we designed and synthesized a series of multidimensional chemotypes and evaluated them for their inhibitory potency using in vitro enzymatic activity and cell-based assay in MCL model. The LCI132 have been shown in vitro ATP-competitive inhibitor of CDK4 / 6 and PI3K kinase activity and acetyl lysine binding bromodomain BRD4 (BD1) inhibition activity. LCI139 demonstrated a potent enzymatic activity against CDK4 / 6 / 9 (IC50= 1.5, 3.6, 0.039 nM, respectively) and PI3Kα (IC50= 70 nM). Additionally, it exhibited potent activity in JeKo-lP (IC50=81.67 nM), JeKo-1 R (IC50= 79.15 nM), and Mino P (IC50= 64.80) MCL systems. LCI133 displayed an excellent potency in panel of human EC cell lines against PTEN-mutant EC cell lines AN3 CA (248 nM), RL95-2 (312 nM), and Ishikawa (123 nM) with minimal potency (>1 pM) against PTEN-wildtype cell lines.Methods:Chemistry Methods.
[0220] All reactions were carried out in oven- or flame-dried glassware under a nitrogen atmosphere unless otherwise noted. Reaction progress was monitored by thin-layer chromatography carried out on silica gel plates (2.5 cm x 7.5 cm, 200 pm thick, 60 F254) and visualized using UV (254 nm) or by potassium permanganate and / or phosphomolybdic acidsolution and / or ninhydrin as an indicator. Flash column chromatography was performed with silica gel (40-63 pm, 60 A) using the mobile phase indicated, or on a Biotage Sekect (Rf 200 UV / vis). Solvents and reagents were purchased from Fisher Scientific, Sigma-Aldrich and used without further purification, except as indicated.
[0221] 1H and13C NMR spectra were recorded on Bruker 400 MHz spectrometers. The chemical shifts of1H NMR are reported in parts per million (ppm) relative to the internal standard tetramethylsilane or residual solvent peak.13C NMR chemical shifts are reported in ppm with the solvents (CDCl3: 77. 23 ppm, CD3OD: 49.15 ppm, DMSO-d6: 39.51 ppm). Multiplicities are indicated by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet), and br (broad). Chemical shifts (δ) are reported in parts per million (ppm) and coupling constants (J) are reported in hertz. High-resolution mass spectra (HRMS) were recorded on a Micromass Q- Tof Mass Spectrometer with an ESI source.
[0222] Experimental procedures for synthesis of multitarget (PI3K-BRD4-CDK4 / 6 / 9- AURKA / B) inhibitors.
[0223] tert-Butyl 4-(8-bromo-4-oxo-4H-chromen-2-yl)piperazine-l -carboxylate (12a) or tert- Butyl 4-(7-bromo-4-oxo-4H-chromen-2-yl)piperazine-l-carboxylate (12b): To a stirred solution of anhydrous THF (5 mL) and lithium diisopropylamide (2.0 M in THF / heptane / ethylbenzene, 13.0 mL, 26 mmol) was added a tert-butyl 4-acetylpiperazine-l -carboxylate (2.56 g, 11.25 mmol) in THF (10 mL) solution at 0 °C. After 1 h, methyl 3-bromo-2-hydroxybenzoate (2.0 g, 8.65 mmol) or methyl 4-bromo-2-hydroxybenzoate (2.0 g, 8.65 mmol) in THF (10 mL) solution was added drop wise over a period of 3 min. The reaction mixture was stirred at room temperature for 12 h and quenched with 10% HC1 solution and extracted with CH2CI2(three, 50 mL extractions). The combined CH2CI2solution was dried over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. The residue was freshly dissolved in CH2CI2(20 mL) and cooled to 0 °C in an ice bath was added trifluoromethanesulfonic anhydride (2.28 mL, 13.5 mmol) drop wise. The reaction mixture was stirred at room temperature for 12 h. The solvent was evaporated in vacuo and MeOH (10 mL) was added and then stirred for 2 h at room temperature. The MeOH was evaporated in vacuo and the reaction mixture was neutralized with aqueous saturated NaHCO3solution and extracted with CH2CI2(three, 50 mL extractions). The combined CH2CI2solution was dried over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. The residue was freshly dissolved in CH2CI2(20 mL) and cooled to 0 °C in an ice bath, di-tert-butyl decarbonate (2.82 g, 13.0 mmol) and A,A-diisopropylethylamine (2.0 mL, 13.0 mmol) were added. The reaction mixture was stirred at room temperature for 12 h and H2O (50 mL) was added and extracted with CH2CI2(three, 50 mL extractions). The combined CH2CI2solution was dried overanhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. The residue was purified by Biotage Selekt flash column chromatography using MeOH / CH2Cl2(1 :20) as an eluent to produce the titled compounds as a brown solid.
[0224] General procedure for Suzuki cross coupling reaction. To a mixture of bromo precursors, i.e., Scheme l-4a, Scheme l-4b, Scheme 3-12a, and Scheme 3-12b (0.2 g, 0.65 mmol), aminophenylboronic acid or aminopyridylboronic acid (0.23 g, 1.29 mmol), Na2CO3(0.2 g, 1.95 mmol) in a mixture of 1,4-dioxane and H2O 1 : 1 (20 mL), and Pd(PPh3)4(0.075 g, 0.065 mmol) under N2 atmosphere were added. The mixture was stirred at 100 °C for 12 h. After cooled to room temperature, the reaction mixture was diluted with H2O (20 mL). The reaction mixture was extracted with CH2Cl2(three, 50 mL extractions) and combined CH2CH2 solution was washed with brine (50 mL). The CH2Cl2solution was dried over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. The residue was purified by Biotage Selekt flash column chromatography using MeOH / CH2Cl2(1 :20) as an eluent.
[0225] General procedure for Buchwald-Hartwig amination reaction. To a stirred suspension of amine or bromo precursors, i.e., 2-chloro-7-cyclopentyl-N,N -dimethyl-7H-pyrrolo[2,3- d ]pyrimidine-6-carboxamide (0.3g, 0.93 mmol) or 2-amino-7-cyclopentyl-N,N -dimethyl-7H - pyrrolo[2,3-d ]pyrimidine-6-carboxamide (0.35g, 1.21 mmol), BINAP (0.056g, 0.09 mmol), NaOtBu (0.18g, 1.86 mmol), and tris(dibenzylideneacetone)dipalladium(0) in a mixture of 1,4- dioxane and toluene (2: 1). The mixture was stirred at 110 °C for 12 h under N2 atmosphere. After cooled to room temperature, the reaction mixture was evaporated to dryness under reduced pressure. The residue was diluted with H2O (50 mL) and extracted with CH2Cl2(three, 50 mL extractions). The combined CH2Cl2solution was dried under anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. The residue was purified by flash column chromatography using EtOAC / MeOH as eluent.
[0226] NMR analysis of the synthesis results for 7-Cyclopentyl-N,N -dimethyl-2-((4-(2- morpholino-4-oxo-4H-chromen-8-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI132):1H NMR (400 MHz, CDCh): δ 8.68 (1H, s, NH), 8.16 (1H, dd, J= 7.83, 1.74 Hz, ArCH), 7.86 (2H, d, J= 8.0 Hz, ArCH), 7.59 (1H, dd, J= 7.40, 1.75, ArCH), 7.50 (2H, d, J= 8.0 Hz, ArCH), 7.43-7.39 (1H, m, ArCH), 6.46 (1H, s, CH), 5.53 (1H, s, CH), 4.81(1H, q, J= 8.92, 8.90 Hz, CH), 3.74 (4H, t, J= 4.92 HZ, (CH2)2), 3.40 (4H, t, J= 4.92 Hz, (CH2)2), 3.17 (6H, s, N(CH3)2), 2.69-2.59 (2H, m, CH2), 2.11-2.04 (4H, m, (CH2)2), 1.76-1.72 (2H, m, CH2).13C NMR (100 MHZ, CDCh): δ 177.39, 164.01, 162.65, 155.21, 151.97, 151.76, 150.70, 140.22, 133.44, 132.16, 130.25, 129.87, 129.31, 124.77, 124.58, 123.42, 117.86, 112.63, 101.01, 87.11, 65.97, 58.00, 44.76, 30.11, 24.70. HRMS-ESI (m / z): [M+H]+calcd for C33H35N6O4, 579.2714; found, 579.2520.
[0227] NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((4-(4-oxo-2- (piperazin-l-yl)-4H -chromen-8-yl)phenyl)amino)-7H -pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI141):1H NMR (400 MHz, CDCl3): δ 8.69 (1H, s, NH), 8.16 (1H, dd, J = 7.75, 1.75 Hz, ArCH), 7.86 (2H, d, J= 8.75 Hz, ArCH), 7.58 (1H, dd, J = 7.38, 1.75, ArCH), 7.51 (2H, d, J = 8.63 Hz, ArCH), 7.41-7.37 (2H, m, ArCH), 6.46 (1H, s, CH), 5.54 (1H, s, CH), 4.81(1H, q, J = 8.92, 8.90 Hz, CH), 3.40 (4H, t, J= 4.92 HZ, (CH2)2), 2.92 (4H, t, J= 4.92 Hz, (CH2)2), 3.17 (6H, s, N(CH3)2), 2.69-2.60 (2H, m, CH2), 2.11-2.05 (4H, m, (CH2)2), 1.74-1.72 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 177.26, 164.03, 162.53, 155.27, 151.98, 151.82, 150.71, 140.15, 133.24, 132.11, 130.15, 129.90, 129.45, 124.61, 124.53, 123.44, 117.83, 112.61, 101.00, 86.87, 77.23, 58.00, 45.79, 45.37, 30.12, 24.70.
[0228] NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((3-(2- morpholino-4-oxo-4H -chromen-8-yl)phenyl)amino)-7H -pyrrolo[2,3-d]pyrimidine-6- carboxamide (LCI138): 'H NMR (400 MHz, CDCh): 3 8.66 (1H, s, NH), 8.20-8.18 (2H, m, ArCH), 7.80 (1H, s, ArCH), 7.63 (1H, dd, J = 7.40, 1.75, ArCH), 7.56 (1H, dd, J = 7.40, 1.75, ArCH), 7.41 (2H, t, J= 7.41 Hz, ArCH), 7.13 (1H, d, J= 7.13 Hz, ArCH), 6.43 (1H, s, CH), 5.51 (1H, s, CH), 4.68(1H, q, J= 9.04, 9.01 Hz, CH), 3.59 (4H, t, J= 4.88 HZ, (CH2)2), 3.32 (4H, t, J = 4.90 Hz, (CH2)2), 3.14 (6H, s, N(CH3)2), 2.48-2.39 (2H, m, CH2), 1.98-1.91 (2H, m, (CH2)2), 1.61-1.55 (2H, m, CH2), 1.46-1.41 (2H, m (CH2)2.13C NMR (100 MHz, CDCh): 3 177.32, 164.03, 162.53, 155.42, 152.04, 151.75, 150.70, 140.54, 137.04, 133.38, 132.27, 130.74, 128.84,125.10, 124.82, 123.42, 122.76, 119.15, 118.11, 112.55, 101.08, 86.96, 65.92, 58.01, 44.76, 30.16,29.78, 24.28. HRMS-ESI (m / z): [M+H]+calcd for C33H35N6O4, 579.2714; found, 579.2393.
[0229] NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((5-(2- morpholino-4-oxo-4H-chromen-8-yl)pyridin-3-yl)amino)-7H -pyrrolo[2,3-J]pyrimidine-6- carboxamide (LCI137):1HNMR (400 MHz, CDCh): 3 8.72-8.68 (2H, m, ArCH), 8.40 (1H, d, J = 1.80 Hz, ArCH), 8.24 (1H, dd, J= 7.87, 1.75 Hz, ArCH), 8.07 (1H, s, NH), 7.70 (1H, s, ArCH), 7.64 (1H, dd, J= 7.38, 1.75 Hz, ArCH), 7.46 (1H, t, J= 7.64 Hz, ArCH), 6.46 (1H, s, ArCH), 5.54 (1H, s, CH), 4.70 (1H, q, J= 9.19, 9.11 Hz, CH), 3.62 (4H, t, J= 4.92 Hz, (CH2)2), 3.32 (4H, t, J = 4.82 Hz, (CH2)2), 3.14 (6H, s, N(CH3)2), 2.42-2.35 (2H, m, CH2), 1.97 (4H, m, (CH2)2), 1.76- 1.69 (2H, m, CH2).13C NMR (100 MHz, CDCh): 3 176.93, 163.79, 162.48, 154.91, 151.82, 151.65, 150.77, 142.63, 139.61, 136.89, 133.36, 132.71, 132.09, 127.19, 125.06, 124.97, 123.53, 113.05, 100.78, 87.16, 65.83, 57.97, 44.71, 30.14, 24.43. HRMS-ESI (m / z): [M+H]+calcd for C32H34N7O4, 580.2667; found, 580.2485.
[0230] NMR analysis of the synthesis results for 7-Cyclopentyl-N,N-dimethyl-2-((4-(2- morpholino-4-oxo-4H-chromen-7-yl)phenyl)amino)-7H-pyrrolo[2,3-J]pyrimidine-6- carboxamide (LCI133):1H NMR (400 MHz, CDCh): δ 8.67 (1H, s, NH), 8.19 (1H, d, J= 8.21 Hz, ArCH), 7.85 (2H, d, J= 8.0 Hz, ArCH), 7.65-7.60 (4H, m, ArCH), 7.51 (1H, d, J= 1.63 Hz, ArCH), 6.45 (1H, s ArCH), 5.52 (1H, s, CH), 4.80 (1H, q, J= 9.10, 8.96 Hz, CH), 3.85 (4H, t, J= 4.92 HZ, (CH2)2), 3.55 (4H, t, J= 4.92 Hz, (CH2)2), 3.17 (6H, s, N(CH3)2), 2.66-2.61 (2H, m, CH2), 2.10-2.04 (4H, m, (CH2)2), 1.76-1.71 (2H, m, CH2).13C NMR (100 MHz, CDCh): 3 177.24, 164.03, 162.86, 155.09, 154.27, 151.99, 151.57, 145.31, 140.72, 132.32, 132.22, 127.65, 126.02, 123.38, 121.23, 118.67, 113.73, 112.60, 101.00, 87.56, 66.05, 58.00, 44.80, 30.20, 29.70, 24.72. HRMS-ESI (m / z): [M+H]+calcd for C33H35N6O4, 579.2714; found, 579.2510.
[0231] NMR analysis of the synthesis results for 7-Cyclopentyl-N,N-dimethyl-2-((5-(2- morphohno-4-oxo-4H -chromen-7-yl)pyridin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6- carboxamide (LCI136):1H NMR (400 MHz, CDCh): δ 8.82 (1H, d, J = 2.31 Hz, ArCH), 8.71 (1H, s, NH), 8.53 (2H, m, ArCH), 8.25 (1H, d, J= 8.10 Hz, ArCH), 7.82 (1H, s, ArCH), 7.55- 7.61 (2H, m, ArCH), 6.46 (1H, s ArCH), 5.55 (1H, s, CH), 4.77 (1H, q, J= 9.02, 8.99 Hz, CH), 3.85 (4H, t, J= 4.82 HZ, (CH2)2), 3.55 (4H, t, J= 4.89 Hz, (CH2)2), 3.15 (6H, s, N(CH3)2), 2.49- 2.39 (2H, m, CH2), 2.06-1.98 (4H, m, (CH2)2), 1.76-1.69 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 176.84, 163.95, 162.83, 155.13, 154.06, 151.98, 151.76, 142.67, 141.19, 140.35, 137.25, 135.08, 132.50, 126.42, 123.98, 123.59, 122.38, 114.92, 113.05, 100.97, 87.66, 66.01, 57.85, 44.79, 30.34, 24.34. HRMS-ESI (m / z): [M+H]+calcd for C32H34N7O4, 580.2667; found, 580.2423.
[0232] NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((2-morpholino- 4-oxo-4H -chromen-7-yl)amino)-7H -pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI139):1H NMR (400 MHz, CDCh): δ 8.71 (1H, s, NH), 8.07 (2H, m, ArCH), 7.60 (1H, s, ArCH), 7.33 (1H, dd, J= 8.63, 2.09 Hz, ArCH), 6.48 (1H, s, ArCH), 5.46 (1H, s ArCH), 4.82 (1H, q, J= 9.02, 8.99Hz, CH), 3.84 (4H, t, J = 4.82 HZ, (CH2)2), 3.50 (4H, t, J = 4.89 Hz, (CH2)2), 3.15 (6H, s, N(CH3)2), 2.66-2.57 (2H, m, CH2), 2.12-2.04 (4H, m, (CH2)2), 1.73-1.69 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 177.18, 163.91, 162.92, 155.11, 154.63, 151.79, 151.74, 144.16,132.63, 126.14, 116.86, 115.58, 113.22, 103.75, 100.95, 87.39, 66.04, 58.05, 44.90, 35.21, 30.15, 24.58. HRMS-ESI (m / z): [M+H]+calcd for C27H31N6O4, 503.58; found, 503.10
[0233] NMR analysis of the synthesis results for 7-Cyclopentyl-N,N-dimethyl-2-((4-oxo-2- (piperazin-l-yl)-4H -chromen-7-yl)amino)-7H -pyrrolo[2,3-J]pyrimidine-6-carboxamide(LCI143): 'H NMR (400 MHz, CDCh): 3 8.69 (1H, s, NH), 8.09 (1H, d, J= 2.13 Hz, ArCH), 8.03 (1H, d, J= 8.63 Hz, ArCH), 7.63 (1H, dd, J= 2.13, 8.63 Hz, ArCH), 6.49 (1H, s, ArCH), 5.49 (1H, s, ArCH), 4.79 (1H, q, J= 9.02, 8.99 Hz, CH), 3.56 (4H, t, J= 5.19 HZ, (CH2)2), 3.17 (6H, s, N(CH3)2), 3.01 (4H, t, J= 5.19 Hz, (CH2)2), 2.66-2.57 (2H, m, CH2), 2.17-2.06 (4H, m, (CH2)2), 1.75-1.71 (2H, m, CH2).13C NMR (100 MHz, CDCh): 3 177.83, 164.19, 163.00, 155.09, 154.61, 151.84, 151.71, 144.43, 132.62, 125.87, 116.30, 115.92, 113.12, 103.80, 101.15, 86.63,77.38, 58.17, 45.49, 45.10, 30.19, 24.59.
[0234] NMR analysis of the synthesis results for 7-Cyclopentyl-N,N-dimethyl-2-((2-morpholino- 4-oxo-4H -chromen-8-yl)amino)-7H -pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI140):1H NMR (400 MHz, CDCl3): δ 8.68 (1H, s, NH), 8.61 (1H, d, J= 9.63 Hz, ArCH), 7.83 (1H, d, J = 7.88 Hz, ArCH), 7.36 (2H, m, ArCH), 6.46 (1H, s, ArCH), 5.54 (1H, s ArCH), 4.77 (1H, q, J = 9.01, 8.88 Hz, CH), 3.82 (4H, t, J= 4.82 HZ, (CH2)2), 3.48 (4H, t, J= 4.89 Hz, (CH2)2), 3.16 (6H, s, N(CH3)2), 2.52-2.47 (2H, m, CH2), 2.10-1.88 (4H, m, (CH2)2), 1.68-1.64 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 177.44, 163.88, 162.33, 155.12, 151.80, 151.75, 144.19, 132.54, 128.39, 124.44, 123.14, 122.69, 118.33, 112.99, 100.78, 87.79, 65.94, 57.93, 44.92, 30.43, 29.71, 24.88. HRMS-ESI (m / z): [M+H]+calcd for C27H31N6O4, 503.24; found, 503.10.
[0235] NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((5-(2- morpholino-4-oxo-4H -chromen-7-yl)-4- (trifluoromethyl)pyridin-2-yl)amino)-7Z7-pyrrolo[2,3- d]pyrimidine-6-carboxamide (LCI144):1H NMR (400 MHz, CDCh): 3 8.90 (1H, s, ArCH), 8.85 (2H, br s, NH, ArCH), 8.36 (1H, s, ArCH), 8.21 (1H, d, J = 7.95 Hz, ArCH), 7.36 (1H, d, J = 8.07, ArCH), 7.33 (1H, s, ArCH), 6.51 (1H, s, ArCH), 5.55 (1H, s ArCH), 4.85 (1H, q, J= 9.01, 8.88 Hz, CH), 3.85 (4H, t, J = 4.82 HZ, (CH2)2), 3.54 (4H, t, J= 4.89 Hz, (CH2)2), 3.17 (6H, s, N(CH3)2), 2.52-2.45 (2H, m, CH2), 2.13-1.98 (4H, m, (CH2)2), 1.76-1.69 (2H, m, CH2).13C NMR (100 MHz, CDCh): 3 176.83, 163.99, 162.83, 153.86, 153.63, 153.26, 151. 84, 150.45,140.88, 137.50, 137.19, 133.03, 126.49, 125.52, 124.46, 122.49, 121.73, 117.49, 113.60, 107.93,107.88, 100.88, 87.66, 66.02, 58.07, 44.77, 30.39, 23.91. HRMS-ESI (m / z): [M+H]+calcd for C33H33F3N7O4, 648.25; found, 503.10.
[0236] NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((5-(2- morpholino-4-oxo-4H -chromen-8-yl)-4-(trifluoromethyl)pyridine-2-yl)amino)-7H -pyrrolo[2,3- d]pyrimidine-6-carboxamide (LCI145):1H NMR (400 MHz, CDCh): 3 8.93 (1H, s, ArCH), 8.81 (1H, s, ArCH), 8.51 (1H, br s, NH), 8.33 (1H, s, ArCH), 8.25 (1H, dd, J= 7.95, 4.00 Hz, ArCH), 7.50 (1H, dd, J= 8.07„ 2.00 Hz, ArCH), 7.42 (1H, t, J= 8.0 Hz, ArCH), 6.51 (1H, s, ArCH), 5.50 (1H, s ArCH), 4.83 (1H, q, J= 9.01, 8.88 Hz, CH), 3.67 (4H, t, J= 4.82 HZ, (CH2)2), 3.20 (4H, t, J= 4.89 Hz, (CH2)2), 3.17 (6H, s, N(CH3)2), 2.52-2.45 (2H, m, CH2), 2.12-1.99 (4H, m, (CH2)2), 1.75-1.68 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 177.56, 164.27, 162.98, 155.14, 154.05, 152.24, 151.26, 145.46, 141.05, 140.10, 132.41, 126.04, 124.14, 122.27, 121.68, 120.53, 114.91, 112.57, 101.18, 87.22.
[0237] NMR analysis of the synthesis results for 7-Cyclopentyl-2-((2-(4-methoxyphenyl)-4-oxo- 4H -chromen-7-yl)amino)-7V,7V-dimethyl-7H -pyrrolo[2,3-J]pyrimidine-6-carboxamide (LCI147):1HNMR (400 MHz, CDCh): 3 8.73 (1H, s, ArCH), 8.39 (1H, d, J= 2.08 Hz, ArCH), 8.15 (1H, d, J = 8.68 Hz, ArCH), 7.88 (2H, d, J= 9.05 Hz, ArCH), 7.68 (1H, s, NH), 7.31 (1H, dd, J = 8.68, 2.08 Hz, ArCH), 7.02 (2H, d, J= 9.05 Hz, ArCH), 6.70 (1H, s, ArCH), 6.49 (1H, s, ArCH), 4.84 (1H, q, J= 9.01, 8.88 Hz, CH), 3.90 (3H, s, 0CH3), 3.18 (6H, s, N(CH3)2), 2.71-2.63 (2H, m, CH2), 2.20-2.12 (4H, m, (CH2)2), 1.80-1.72 (2H, m, CH2).13C NMR (100 MHz, CDCh): 3 177.79, 163.91, 163.22, 162.20, 157.80, 154.47, 151.77, 151.68, 145.05, 132.80, 127.95, 126.24, 124.51, 117.97, 116.19, 114.33, 113.35, 106.42, 104.38, 100.89, 58.25, 55.52, 3017, 14.59.
[0238] NMR analysis of the synthesis results for 7-Cyclopentyl-2-((2-(4-methoxyphenyl)-4-oxo- 4H -chromen-8-yl)amino)-A,A-dimethyl-7H -pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI148):1H NMR (400 MHz, CDCh): δ 8.90 (1H, dd, J = 8.07, 1.59 Hz, ArCH), 8.74 (1H, s, ArCH), 7.89 (2H, d, J= 9.05 Hz, ArCH), 7.85 (1H, dd, J= 7.95, 1.59 Hz, ArCH), 7.81 (1H, s, NH), 7.42 (1H, t, J= 8.01 Hz, ArCH), 7.06 (2H, d, J= 9.05 Hz, ArCH), 6.77 (1H, s, ArCH), 6.48 (1H, s, ArCH), 4.80 (1H, q, J= 8.68, 8.56 Hz, CH), 3.91 (3H, s, 0CH3), 3.17 (6H, s, N(CH3)2), 2.63-2.54 (2H, m, CH2), 2.17-2.03 (4H, m, (CH2)2), 1.77-1.67 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 178.51, 163.94, 162.65, 162.45, 154.94, 151.80, 151.77, 145.88, 132.57, 129.80, 128.01, 124.82, 124.05, 123.92, 122.02, 117.32, 114.71, 113.14, 106.62, 100.83,57.99, 55.55, 30.38, 24.88.
[0239] NMR analysis of the synthesis results for 3-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H - pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5-(2-morpholino-4-oxo-4H7-chromen-7-yl)benzoic acid (LCI149):1H NMR (400 MHz, CDCI3+CD3OD): δ 8.65 (1H, s, ArCH), 8.42 (1H, s, ArCH), 8.37 (1H, s, ArCH), 8.19 (1H, d, J= 8.0 Hz, ArCH), 8.00 (1H, s, ArCH), 7.67 (1H, d, J= 8.0, ArCH), 7.62 (1H, s, ArCH), ’6.46 (1H, s ArCH), 5.57 (1H, s, ArCH), 4.72 (1H, q, J= 9.01, 8.88 Hz, CH), 3.85 (4H, t, J= 4.82 HZ, (CH2)2), 3.59 (4H, t, J= 4.89 Hz, (CH2)2), 3.15 (6H, s, N(CH3)2), 2.45 (2H, br s, CH2), 2.00 (2H, br s, CH2), 1.76-1.41 (4H, m, (CH2)2).13C NMR (100 MHz, CDCI3+CD3OD): δ 177.56, 164.27, 162.98, 155.14, 154.05, 152.24, 151. 26, 145.46, 141.05, 140.10, 132.41, 126.04, 124.14, 122.27, 121.68, 120.53, 114.91, 112.57, 101.18, 87.22, 66.07,57.88, 44.79, 30.42, 29.75, 24.20.
[0240] 3-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-5- (2-morpholino-4-oxo-4H-chromen-8-yl)benzoic acid (LCI150). 1H NMR (400 MHz, CDCI3+CD3OD): 5 8.66 (1H, s, ArCH), 8.45 (1H, s, ArCH), 8.26 (1H, t, J= 1.6 Hz, ArCH), 8.17 (1H, dd, J = 7.9, 1.8 Hz, ArCH), 7.93 (1H, t, J= 1.6 Hz, ArCH), 7.72 (1H, dd, J = 7.4, 1.8 Hz, ArCH), 7.47 (1H, t, J= 7.6 Hz, ArCH), 6.47 (1H, s, ArCH), 5.58 (1H, s, ArCH), 4.71-4.62 (1H, m, CH), 3.67 (4H, t, J= 4.8 HZ, (CH2)2), 3.43 (4H, t, J= 4.8 Hz, (CH2)2), 3.16 (6H, s, N(CH3)2), 2.36 (2H, br s, CH2), 1.96 (2H, br s, CH2), 1.76-1.36 (4H, m, (CH2)2).13C NMR (100 MHz, CDCI3+CD3OD): δ 177.80, 168.57, 164.23, 162.60, 155.00, 152.04, 151.33, 150.53, 140.87, 136.71, 133.53, 132.39, 131.27, 129.83, 125.15, 124.19, 123.32, 122.96, 119.78, 112.53, 101.19, 86.41, 65.92, 57.93, 44.77, 30.18, 29.69, 23.99. HRMS-ESI (m / z): [M+H]+calcd for C34H35N6O6, 623.26; found, 623.05.
[0242] NMR analysis of the synthesis results for Synthesis of 7-cyclopentyl-N,N-dimethyl-2-(N- (2-morpholino-4-oxo-47 / -chromen-7-yl)acrylamido)-77 / -pyrrolo[2,3-t / ]pyrimidine-6- carboxamide (LCI151):1H NMR (400 MHz, CDCI3): δ 8.88 (1H, s, ArCH), 8.14 (1H, d, J= 8.4 Hz, ArCH), 7.34 (1H, d, J= 1.9 Hz, ArCH), 7.11 (1H, dd, J = 8.5, 2.0 Hz, ArCH), 6.55 (1H, s, ArCH), 6.54 (1H, dd, J= 16.8, 10.1 Hz), 6.41 (1H, dd, J= 16.8, 10.1 Hz), 5.72 (1H, dd, J= 10.1, 1.9 Hz), 5.49 (1H, s, ArCH), 4.74 (1H, q, J= 9.01, 8.88 Hz, CH), 3.81 (4H, t, J = 4.82 HZ, (CH2)2), 3.49 (4H, t, J= 4.82 Hz, (CH2)2), 3.18 (3H, s, CH3), 3.14 (3H, s, CH3), 2.32-2.22 (2H, m, CH2), 2.07-1.99 (2H, m, CH2), 1.85-1.78 (2H, m, CH2), 1.57-1.50 (2H, m, CH2).13C NMR (100 MHz, CDCl3): δ 176.68, 166.75, 163.25, 162.79, 154.36, 153.89, 151.55, 151.26, 145.13, 136.04, 130.40, 128.42, 126.28, 123.93, 121.43, 116.47, 115.42, 99.67, 87.45, 66.00, 58.21, 44.77, 39.24, 35.15, 31.24, 24.90.NMR analysis of the synthesis results for 7-Cyclopentyl-A,A-dimethyl-2-((5-(2-morpholino-4- oxo-4H -chromen-8-yl)pyridin-2-yl)amino)-7H -pyrrolo[2,3-J]pyrimidine-6-carboxamide (LCI153).1H NMR (400 MHz, CDCI3+CD3OD): δ 8.76 (1H, s, ArCH), 8.65 (1H, d, J= 8.65 Hz, ArCH), 8.47 (1H, d, J= 2.38 Hz, ArCH), 8.17 (1H, dd, J= 7.88, 1.75, ArCH), 7.88 (1H, dd, J = 8.76, 2.38 Hz, ArCH), 7.62 (1H, dd, J= 7.38, 1.75 Hz, ArCH), 7.47 (1H, t, J= 7.69 Hz, ArCH), 6.51 (1H, s, CH), 5.59 (1H, s, CH), 4.80 (1H, q, J= 8.92, 8.90 Hz, CH), 3.77 (4H, t, J= 5.0 HZ, (CH2)2), 3.44 (4H, t, J= 5.00 Hz, (CH2)2), 3.18 (6H, s, N(CH3)2), 2.64-2.59 (2H, m, CH2), 2.14- 2.08 (4H, m, (CH2)2), 1.79-1.76 (2H, m, CH2).13C NMR (100 MHz, CDCI3+CD3OD): δ 175.18, 161.57, 160.21, 151.34, 150.13, 149.27, 149.13, 148.15, 145.50, 136.03, 131.04, 130.17, 124.51, 122.69, 122.62, 120.60, 110.78, 108.83, 98.50, 84.31, 63.37, 55.55, 42.21, 36.94, 32.71, 27.62, 22.18. HRMS-ESI (m / z): [M+H]+calcd for C32H34N7O4, 580.27; found, 580.10.7-Cyclopentyl-2-((3-fluoro-4-(2-morpholino-4-oxo-47 / -chromen-8-yl)phenyl (amino)-N,N- dimethyl-77 / -pyrrolo[2,3-t / ]pyrimidine-6-carboxamide (LCI154).1H NMR (400 MHz, CDCh): δ 8.70 (1H, s, ArCH), 8.20 (1H, dd, J= 7.87, 1.74 Hz, ArCH), 8.13 (1H, dd, J= 13.05, 2.10 Hz, ArCH), 7.58 (1H, dd, J = 7.45, 1.74, ArCH), 7.42 (1H, t, J = 8.19 Hz ArCH), 7.41 (1H, NH, overlapped), 7.33 (1H, t, J= 8.19 Hz, ArCH), 7.25 (1H, dd, J= 7.45, 1.74 Hz, ArCH), 6.47 (1H, s, ArCH), 5.52 (1H, s, CH), 4.79 (1H, q, J= 9.17, 8.97 Hz, CH), 3.73 (4H, t, J= 5.0 HZ, (CH2)2), 3.36 (4H, t, J= 5.0 Hz, (CH2)2), 3.21 (6H, s, N(CH3)2), 2.70-2.63 (2H, m, CH2), 2.14-2.05 (4H, m, (CH2)2), 1.79-1.71 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 175.36, 162.01, 160.61, 158.17 (d, J = 244.0 Hz), 152.87, 149.95, 149.81, 149.17, 140.35 (d, J= 11.0 Hz), 132.15, 130.65, 129.68 (d, J = 6.0 Hz), 123.44, 122.82, 122.71, 121.35, 114.39 (d, J = 17 Hz), 111.72, 111.09, 102.95 (d, J = 28 Hz), 98.99, 85.21 64.07, 56.35, 42.75, 37.52, 33.29, 28.11, 22.53. HRMS-ESI (m / z): [M+H]+calcd for C33H34FN6O4, 597.2620; found, 597.2583.7-Cyclopentyl-A,A-dimethyl-2-((4-(4-oxo-2-(piperazin-l-yl)-4H -chromen-7-yl)phenyl)amino)- 7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI152).1HNMR (400 MHz, CDCh): δ 8.68 (1H, s, NH), 8.18 (1H, d, J= 8.20 Hz, ArCH), 7.84 (2H, d, J = 8.75 Hz, ArCH), 7.63 (2H, d, J= 8.75 Hz, ArCH), 7.60 (1H, dd, J= 7.38, 1.75, ArCH), 7.51 (1H, d, J = 1.6 Hz, ArCH), 7.42 (1H, br s, ArCH), 6.45 (1H, s, ArCH), 5.55 (1H, s, ArCH), 4.81(1H, q, J= 8.92, 8.90 Hz, CH), 3.59 (4H, t, J= 4.92 HZ, (CH2)2), 3.16 (6H, s, N(CH3)2), 3.06 (4H, t, J= 4.92 Hz, (CH2)2), 2.68-2.61 (2H, m, CH2), 2.12-2.09 (4H, m, (CH2)2), 1.76-1.71 (2H, m, CH2).13C NMR (100 MHz, CDCl3): δ 176.72, 163.59, 162.26, 154.69, 153.76, 151.50, 151.27, 144.71, 140.21, 131.88, 131.66, 127.18, 125.45, 122.81, 120.69, 118.17, 113.24, 112.17, 100.49,86.88, 57.50, 44.97, 44.72, 38.95, 34.71, 29.74, 24.25. HRMS-ESI (m / z): [M+H]+calcd for C33H36N7O3, 578.29; found, 578.00.
[0001] NMR analysis of the synthesis results 7-cyclopentyl-A,A-dimethyl-2-((3-methyl-2- morphohno-4-oxo-4H-chromen-7-yl)amino)-7J7-pyrrolo[2,3-J]pyrimidine-6-carboxamide (LCI156).1H NMR (400 MHz, CDCh): δ 8.71 (1H, dd, J= 8.02, 1.53 Hz, ArCH), 8.68 (1H, s, ArCH), 7.79 (1H, dd, J= 7.94, 1.50 Hz, ArCH), 7.43 (1H, s, NH), 7.34 (1H, t, J= 7.99 Hz, ArCH), 6.44 (1H, s, ArCH), 4.76 (1H, q, J= 8.95, 8.94 Hz, CH), 3.85 (4H, t, J= 4.82 HZ, (CH2)2), 3.42 (4H, t, J= 4.89 Hz, (CH2)2), 3.14 (6H, s, N(CH3)2), 2.56-2.46 (2H, m, CH2), 2.09-1.95 (4H, m, (CH2)2), 2.05 (3H, s, CH3), 1.73-1.64 (2H, m, CH2).13C NMR (100 MHz, CDCh): 3 179.02, 164.05, 161.38, 155.13, 151.98, 151.90, 143.80, 132.57, 128.98, 124.47, 122.52, 121.39, 117.90, 113.14, 103.77, 100.98, 66.80, 58.07, 48.64, 39.55, 35.32, 30.47, 24.98, 10.96. HRMS-ESI (m / z): [M+H]+calcd for C28H33N6O4, 517.2558; found, 517.2552.7-Cyclopentyl-2-((3-fluoro-4-(3-methyl-2-morpholino-4-oxo-4Z7-chromen-8-yl)phenyl)amino)- N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (LCI158).1H NMR (400 MHz, CDCh): 3 8.70 (1H, s, ArCH), 8.23 (1H, dd, J= 7.94, 1.69 Hz, ArCH), 8.14 (1H, dd, J= 13.01, 2.13 Hz, ArCH), 7.59 (1H, dd, J= 7.38, 1.75 Hz, ArCH), 7.44-7.40 (2H, m, ArCH and NH), 7.32 (1H, t, J= 8.19 Hz ArCH), 7.26 (1H, dd, J = 8.38, 2.13 Hz, ArCH), 6.47 (1H, s, ArCH), 4.79 (1H, q, J= 9.17, 8.97 Hz, CH), 3.69 (4H, t, J= 5.0 HZ, (CH2)2), 3.28 (4H, t, J= 5.0 Hz, (CH2)2), 3.17 (6H, s, N(CH3)2), 2.71-2.63 (2H, m, CH2), 2.11-2.08 (4H, m, (CH2)2), 2.05 (3H, CH3), 1.75- 1.70 (2H, m, CH2).13C NMR (100 MHz, CDCl3): δ 178.13, 163.33, 161.34, 159.56 (d, J= 244.0 Hz), 154.21, 151.21, 151.11, 150.48, 141.56 (d, J = 12.0 Hz), 133.17, 131.88 (d, J = 5.0 Hz),124.90, 124.51, 123.77, 122.02, 115.64 (d, J = 17 Hz), 112.94, 112.35, 104.23 (d, J = 29 Hz), 101.69, 100.28, 66.03, 57.65, 47.71, 38.80, 34.60, 29.398, 23.78, 10.31. HRMS-ESI (m / z): [M+H]+calcd for C34H36FN6O4, 611.2777; found, 611.2794.7-Cyclopentyl-2-((3-fluoro-2-(4-methoxyphenyl)-4-oxo-47 / -chromen-7-yl (amino)-N,N- dimethyl-77 / -pyrrolo[2,3-t / ]pyrimidine-6-carboxamide (LCI157).1H NMR (400 MHz, CDCh): δ8.72 (1H, s, ArCH), 8.43 (1H, d, J= 2.01, ArCH), 8.18 (1H, d, J= 8.72, ArCH), 7.97 (2H, d, J = 8.42), 7.66 (1H, s, NH), 7.27 (1H, dd, J= 8.78, 2.05 Hz, ArCH), 7.03 (2H, d, J= 8.42 Hz, ArCH), 6.48 (1H, s, ArCH), 4.80 (1H, q, J = 8.68, 8.56 Hz, CH), 3.89 (3H, s, OCH3), 3.16 (6H, s, N(CH3)2), 2.69-2.59 (2H, m, CH2), 2.16-2.07 (4H, m, (CH2)2), 1.77-1.67 (2H, m, CH2).13C NMR (100 MHz, CDCh): δ 170.32 (J= 18.9 Hz), 163.98, 162.00, 156.87, 154.43, 151.91, 151.72,150.72 (J = 25.0 Hz), 145.82 (J = 245 Hz), 145.40, 133.05, 129.93 (J = 8.0 Hz), 126.51 (J= 4. 0 Hz), 121.60 (J = 5. 0 Hz), 118.22 (J = 7.0 Hz), 116.46, 114.33, 113.61, 104.14, 101.02, 58.38, 55.64, 39.57, 35.35, 30.27, 24.69. F19NMR (376 MHz, CDC13): -163.39.NMR analysis of the synthesis results 7-((4-(4-Fluoro-l-isopropyl-2-methyl-lH- benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)-2-morpholino-4H-chromen-4-one (LCI163).1H NMR (400 MHz, CDCI3+CD3OD): δ 8.54 (1H, d, J = 5.3 Hz, ArCH), 8.35 (1H, d, J = 2.0 Hz, ArCH), 8.09-8.01 (2H, m, ArCH), 7.77 (1H, dd, J = 11.6, 1.3 Hz, ArCH), 7.41 (1H, dd, J = 8.6, 2.1 Hz, ArCH), 7.30 (1H, d, J= 5.3 Hz), 5.49 (1H, s, ArCH), 4.75 (1H, h, J = 7.0 Hz, CH), 3.86 (4H, t, J= 4.82 HZ, (CH2)2), 3.58 (4H, t, J= 4.82 Hz, (CH2)2), 2.69 (3H, s, CH3), 1.73 (6H, d, J = 7.0 Hz, (CH3)2).13C NMR (100 MHz, CDCh): δ 176.08, 162.83, 161.30, 157.81, 156.89, 153.15, 152.00, 151.78 (d, J = 250 Hz), 142.39, 134.96 (d, J = 9.0 Hz), 131.94 (d, J = 17 Hz), 129.79 (d, J = 7.0 Hz), 124.11, 114.96, 114.39, 107.50, 105.01, 104.81, 103.22, 84.83, 75.62,64.36, 47.06, 43.04, 19.74, 13.11. F19 NMR (376 MHz, CDC13+CD3OD): -129.01. HRMS-ESI (m / z): [M+H]+calcd for C28H28FN6O3, 515.2201; found, 515.2208.
[0002] NMR analysis of the synthesis results for Synthesis of 2-morpholino-8-(quinolin-7-yl)- 47 / -chromen-4-one (LCI28):1H NMR (400 MHz, CDCh): δ 8.98 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 8.30 (1H, d, J= 4.0 Hz, ArCH), 8.24-8.29 (2H, m, ArCH), 7.92 (1H, d, J= 8.0 Hz, ArCH), 7.74 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.71 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.42-7.49 (2H, m, ArCH), 5.54 (1H, s, CH), 3.70 (4H, t, J= 4.0 HZ, (CH2)2), 3.35 (4H, t, J= 4.0 HZ, (CH2)2).13C NMR (100 MHz, CDCh): 3 177.07, 162.57, 151.20, 150.69, 148.22, 137.51, 135.84, 133.74, 130.14, 129.51, 128.03, 127.72, 127.65, 125.70, 124.98, 123.60, 121.63, 87.19, 65.90, 44.80. HRMS-ESI (m / z): [M+H]+calcd for C22HI9N2O3, 359.1390; found, 359.1314.
[0003] NMR analysis of the synthesis results for Synthesis of 2-morpholino-8-(quinolin-6-yl)- 47 / -chromen-4-one (LCI29):1H NMR (400 MHz, CDCh): δ 8.99 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 8.19-8.25 (3H, m, ArCH), 7.97 (1H, d, J= 4.0 Hz, ArCH), 7.92 (1H, d, J= 8.0 Hz, ArCH), 7.69 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.48-7.53 (2H, m, ArCH), 5.55 (1H, s, CH), 3.69 (4H, t, J= 4.0 HZ, (CH2)2), 3.32 (4H, t, J= 4.0 HZ, (CH2)2).13C NMR (100 MHz, CDCh): δ 177.08, 162.55, 151.04, 150.74, 147.73, 136.02, 134.80, 133.71, 130.97, 129.50, 129.31, 128.33, 125.67, 124.95, 123.55, 121.89, 87.19, 65.86, 44.74. HRMS-ESI (m / z): [M+H]+calcd for C22H19N2O3, 359.1390; found, 359.1302.
[0004] NMR analysis of the synthesis results for Synthesis of 8-(2,3-dihydrobenzo[b][l,4]dioxin- 6-yl)-2-morpholino-4H-chromen-4-one (LCI30):1H NMR (400 MHz, CDCh): δ 8.14 (1H, dd, J = 8.0, 4.0 Hz, ArCH), 7.53 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.37 (1H, t, J= 8.0 Hz, ArCH), 7.06 (1H, d, J= 4.0 Hz, ArCH), 7.00 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 6.94 (1H, d, J= 8.0 Hz, ArCH), 5.51 (1H, s, CH), 4.31 (4H, m, (CH2)2), 3.75 (4H, t, J= 4.0 HZ, (CH2)2), 3.39 (4H, t, J= 4.0 HZ, (CH2)2).13C NMR (100 MHZ, CDCl3): δ 177.31, 162.56, 150.58, 143.52, 143.48, 133.29, 129.74,129.51, 124.73, 123.40, 122.52, 118.42, 117.12, 87.02, 65.99, 64.53, 64.40, 44.82. HRMS-ESI (m / z): [M+H]+calcd for C21H20NO5, 366.1336; found, 366.1284.
[0005] NMR analysis of the synthesis results for Synthesis of 7-(2-morpholino-4-oxo-4H- chromen-8-yl)quinoline-4-carbonitrile (LCI35):1H NMR (400 MHz, CDCI3): δ 9.11 (1H, d, J = 4.0 Hz, ArCH), 8.40 (1H, d, J= 4.0 Hz, ArCH), 8.28- 8.34 (2H, m, ArCH), 8.07 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.82 (1H, d, J= 4.0 Hz, ArCH), 7.72 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.51 (1H, t, J= 8.0 Hz, ArCH), 5.57 (1H, s, CH), 3.73 (4H, t, J= 4.0 HZ, (CH2)2), 3.36 (4H, t, J= 4.0 HZ, (CH2)2).13C NMR (100 MHZ, CDCl3): δ 176.91, 162.73, 150.78, 150.11, 147.71, 137.79, 134.10, 133.01, 130.68, 128.43, 126.62, 125.87, 125.62, 125.36, 125.28, 123.90, 118.69, 115.53, 87.56, 65.96, 44.92. HRMS-ESI (m / z): [M+H]+calcd for C23H18N3O3, 384.1343; found, 384.1275.
[0006] NMR analysis of the synthesis results for Synthesis of 7-(2-morpholino-4-oxo-4H- chromen-8-yl)quinoline-4-carboxamide (LCI36):1H NMR (400 MHz, DMSO-d6): δ 9.03 (1H, d, J= 4.0 Hz, ArCH), 8.48 (1H, d, J= 4.0 Hz, ArCH), 8.32 (1H, s, NH), 8.21 (1H, d, J= 8.0 Hz, ArCH), 8.02- 8.08 (2H, m, ArCH), 7.94 (1H, s, NH), 7.80 (1H, dd, J= 8.0, 4.0 Hz, ArCH), 7.66 (1H, d, J= 8.0 Hz, ArCH), 7.54 (1H, t, J= 8.0 Hz, ArCH), 5.60 (1H, s, CH), 3.63 (4H, t, J= 4.0 HZ, (CH2)2), 3.36 (4H, (CH2)2, overlapped).13C NMR (100 MHz, DMSO-d6): δ 174.93, 168.46, 162.31, 150.85, 150.11, 147.41, 141.94, 134.45, 133.85, 131.24, 129.65, 129.10, 126.02, 125.03, 124.76, 123.87, 123.28, 119.66, 86.25, 65.17, 44.46. HRMS-ESI (m / z): [M+H]+calcd for C23H20N3O4, 402.1448; found, 402.1340.NMR analysis of the synthesis results for Synthesis of 8-(4-methoxyquinolin-7-yl)-2-morpholino- 4H-chromen-4-one (LCI40):1H NMR (400 MHz, CDC13): δ 8.82 (1H, d, J = 5.04 Hz, ArCH), 8.42 (1H, s, ArCH), 8.23 (1H, d, J= 7.88 Hz, ArCH), 8.13 (1H, d, J= 8.71 Hz, ArCH), 7.88 (1H, d, J= 8.69 Hz, ArCH), 7.71 (1H, d, J= 7.47 Hz, ArCH), 7.46 (1H, t, J= 7.62 Hz, ArCH), 6.83 (1H, d, J= 5.24 Hz, ArCH), 5.55 (1H, s, CH), 4.09 (3H, s, OCH3), 3.70 (4H, t, J= 4.0 HZ, (CH2)2), 3.36 (4H, (CH2)2).13C NMR (100 MHz, CDC13): δ 177.28, 162.67, 162.50, 152.13, 150.85, 148.70, 133.92, 133.75, 131.32, 129.85, 129.11, 125.59, 125.06, 123.67, 122.77, 121.37, 100.80, 87.22, 66.06, 56.01, 44.89. HRMS-ESI (m / z): [M+H]+calcd for C23H21N2O4, 389.1496; found, 389.1471.NMR analysis of the synthesis results for 8-(4-methoxyquinolin-7-yl)-2-morpholino-4H-chromen- 4-one (LCI72):1H NMR (400 MHz, CDCI3): δ 8.81 (1H, d, J= 5.2 Hz, ArCH), 8.28 (1H, d, J = 8.5 Hz, ArCH), 8.24 (1H, dd, J= 7.8, 1.7 Hz, ArCH), 8.20 (1H, d, J= 1.7 Hz, ArCH), 7.69 (2H, td, J= 8.2, 1.8 Hz, ArCH), 7.47 (1H, t, J= 7.6 Hz, ArCH), 6.81 (1H, d, J= 5.2 Hz, ArCH), 5.55 (1H, s, CH), 4.10 (3H, s, OCH3), 3.70 (4H, t, J= 4.9 Hz, (CH2)2), 3.35 (4H, t, J= 4.9 Hz, (CH2)2). 13C NMR (100 MHz, CDCI3): δ 176.59, 162.05, 161.74, 151.66, 150.17, 148.64, 137.30, 133.22, 129.10, 129.05, 126.48, 125.09, 126.48, 125.09, 124.43, 123.04, 121.38, 120.28, 100.05, 86.62, 65.40, 55.28, 44.27. HRMS-ESI (m / z): [M+H]+calcd for C23H21N2O4, 389.1496; found, 389.05.NMR analysis of the synthesis results for Synthesis of 3-methyl-2-morpholino-8-(quinolin-6-yl)- 4H-chromen-4-one (LCI73):1HNMR (400 MHz, CDCI3): δ 8.80 (1H, d, J= 5.2 Hz, ArCH), 8.40 (1H, dd, J= 2.1, 0.6 Hz, ArCH), 8.23 (1H, dd, J= 7.9, 1.7 Hz, ArCH), 8.11 (1H, dd, J= 8.8, 0.6 Hz, ArCH), 7.87 (2H, dd, J= 8.8, 2.1 Hz, ArCH), 7.70 (1H, dd, J= 7.4, 1.7 Hz, ArCH), 7.44 (1H, t, J= 7.9 Hz, ArCH), 6.80 (1H, d, J= 5.2 Hz, ArCH), 4.06 (3H, s, OCH3), 3.65 (4H, t, J= 4.9 Hz, (CH2)2), 3.25 (4H, t, J = 4.9 Hz, (CH2)2), 2.04 (3H, s, CH3).13C NMR (100 MHz, CDCI3): δ178.81, 162.47, 162.07, 152.09, 150.87, 148.70, 133.70, 133.57, 131.36, 130.17, 128.99, 125.73,124.81, 123.06, 122.84, 121.27, 102.43, 100.74, 66.75, 55.96, 53.58, 48.64, 11.12. HRMS-ESI (m / z): [M+H]+calcd for C24H23N2O4+, 403.45; found, 403.46
[0007] NMR analysis of the synthesis results for Synthesis of 2-(piperazin-l-yl)-8-(quinolin-7- yl)-4 / / -chromen-4-one (LCI53):1H NMR (400 MHz, CDCI3+CD3OD): δ 8.94 (1H, d, J= 6.13 Hz, ArCH), 8.30-8.27 (2H, m, ArCH), 8.21 (1H, dd, J = 7.88, 1.75 Hz, ArCH), 7.97 (1H, s, ArCH), 7.95 (1H, s, ArCH), 7.76 (1H, dd, J = 8.38, 1.75 Hz, ArCH), 7.73 (1H, dd, J = 7.50, 1.75 Hz, ArCH), 7.54-7.48 (2H, m, ArCH), 5.60 (1H, s, CH), 3.41 (4H, t, J= 4.94 HZ, (CH2)2), 2.89 (4H, t, J = 4.94 Hz, (CH2)2).13C NMR (100 MHZ, CDCI3+CD3OD): δ 177.65, 162.53, 151.00, 150.64, 147.80, 137.81, 136.51, 133.98, 129.53, 129.45, 128.30, 127.95, 127.82, 125.59, 125.22, 123.19, 121.79, 86.74, 45.31, 44.84. LCMS-ESI (m / z): [M+H]+calcd for C22H20N3O2, 358.16; found, 358.05.
[0008]
[0009] NMR analysis of the synthesis results for A-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3- yl)methyl)-3-fluoro-4-(2-morpholino-4-oxo-4Z7-chromen-8-yl)benzamide (LCI161).1H NMR (400 MHz, DMSO-d6): δ 11.53 (1H, br s, NH), 8.61 (1H, t, J= 4.88, NH), 8.03 (1H, dd, J= 7.77, 1.71 Hz, ArCH), 7.87-7.83 (2H, m, ArCH), 7.70-7.63 (2H, m, ArCH), 7.50 (1H, t, J= 7.63 Hz, ArCH), 5.89 (1H, s, ArCH), 5.58 (1H, s, ArCH), 4.33 (2H, d, J= 5.2 Hz, CH2), 3.62 (4H, t, J = 4.94 HZ, (CH2)2), 3.31 (4H, t, J = 4.94 Hz, (CH2)2), 2.20 (3H, s, CH3), 2.13 (3H, s, CH3).13C NMR (100 MHz, DMSO-d6): 3 174.77, 164.29, 163.06, 161.88, 158.77 (d, J= 245 Hz), 150.22, 149.85, 142.94, 136.68, 134.00, 131.94, 125.76 ( J = 16 Hz), 125.29, 124.78, 123.71, 123.35, 122.91, 121.34, 114.56 (d, J= 24 Hz), 107.47, 86.14, 65, 16, 44.38, 35.61, 18.97, 18.22.
[0010]
[0011]
[0012]
[0013] NMR analysis of the synthesis results for 3-fluoro-7V-((4-methoxy-6-methyl-2-oxo-l,2- dihydropyridin-3-yl)methyl)-4-(2-morpholino-4-oxo-4H-chromen-8-yl)benzamide (LCI162).1H NMR (400 MHz, DMSO-d6): δ 11.53 (1H, br s, NH), 8.41 (1H, t, J= 4.88, NH), 8.03 (1H, dd, J = 7.82, 1.71 Hz, ArCH), 7.84 (lH, t, J= 2.02 Hz, ArCH), 7.81 (1H, dd, J= 5.32, 1.65 Hz, ArCH), 7.71-7.63 (2H, m, ArCH), 7.51 (1H, t, J= 7.64, ArCH), 6.14 (1H, s, ArCH), 5.58 (1H, s, ArCH), 4.26 (2H, d, J= 4.40 Hz, CH2), 3.82 (3H, s, OCH3), 3.63 (4H, t, J= 4.94 HZ, (CH2)2), 3.30 (4H, t, .7= 4.94 Hz, (CH2)2), 2.21 (3H, s, CH3).13C NMR (100 MHz, DMSO-d6): 3 174.78, 166.14,
[0014] 164.16, 163.81, 161.89, 158.78 (d, J = 246 Hz), 150.23, 145.91, 136.91 (d, J= 7.0 Hz), 134.01, 131.95, 125.66 (d, J= 16 Hz), 125.28, 124.78, 123.61, 123.37, 122.91, 114.46 (d, J= 24 Hz), 104.93, 93.47, 86.14, 65.15, 56.14, 44.37, 33.41, 18.83.
[0015]
[0016] Biology. Human MCL cell lines (JeKo-1 and Mino), EC cell lines (AN3 CA, RL95-2, HEC-l-A, HEC-l-B, and KLE), and NSCLC cell lines (NCI-H1975, NCI-H1703, NCI-H1781, NCI-H1373, NCI-H226, and Calu-3) were purchased from ATCC (Manassas, VA) and EC cell line Ishikawa was purchased from Sigma-Aldrich (St. Louis, MO). JeKo-1 and Mino ibrutinib resistance were generated in-house at the Durden laboratory by gradually increasing the concentration of ibrutinib for a period of over six months. Ibrutinib resistance was confirmed by IC50determination from cell viability assay. HS-5 stromal cells were received from ATCC (Manassas, VA). All cell lines were authenticated by STR profiling. Normal human B-cells were acquired from healthy donor at Atrium Health Levine Cancer Institute according to a blanket institutional IRB protocol.
[0017] Kinase inhibition assays. Kinase activity assays were carried out by Reaction Biology (Malvern, PA) to measure IC50 of the LCI candidates for CDK2 / 4 / 6 / 7 / 9, AURKA / B, PI3Ka,PI3Kγ, and PI3Kδ. Alpha Screen assays were carried out by Reaction Biology (Malvern, PA) to measure IC50 of the LCI multidimensional inhibitors for His-tagged BRD4(BD1) and BRD4(BD2) bromodomains.
[0018] Cell Viability assay. MCL (parental and ibrutinib resistant) cells were seeded in 96-well plates at a density of 2x104while EC and NSCLC cells were seeded in a 96-well plate at a density of 1x104in 100 μL of media. Cells were treated with DMSO (0.1%) or increasing concentration of the indicated inhibitors for 48 h. Cell viability was analyzed by CellTiter Glo (Promega) or WST-8 (Abeam) assay reagent. Averaged values were normalized as a percentage of DMSO (control) and analyzed by nonlinear regression then plotted for dose response using GraphPad Prism (GraphPad Software, Inc).
[0019] Cytotoxicity assay of non-transformed cells. Healthy doner primary B-cells (50,000 / well) or HS-5 stromal cells (5,000 / well) were treated with DMSO control or increasing concentration of LCI132 and combination of ribociclib, PLX51107, and BKM-120 for 48 h in 96-well plate. Cell viability was analyzed by CellTiter Gio (Promega) assay reagent. Averaged values were normalized as a percentage of DMSO (control) and analyzed for dose response by GraphPad Prism (GraphPad Software, Inc).
[0020] FITC Annexin V apoptosis assay. JeKo-1 and Mino cells were seeded at a density of 1x106cells and treated with the specified concentration of LCI28, LCI132, and LCI133 or DMSO (Control) for 24 h. Cells were harvested and washed twice with cold PBS and labeled with 7AAD (Thermo Fisher) and Annexin V FITC (BD Bioscience) according to the manufacture protocol. The labeled cells were analyzed using an Accuri C6 (BD Biosciences) or NovoCyte 2060R (ACEA Biosciences Inc.) flow cytometer.
[0021] Cell Cycle analysis. MCL (parental and ibrutinib resistant), EC, or NSCLC cells were treated with the specified concentrations of single agent inhibitor, LCI28, LCI132, LCI133, or LCI139 for 24 h. Cells were harvested, washed once with PBS, and then resuspend with DPBS. Cells were further stained with Vybrant DyeCycle Violet (Thermofisher Scientific) for 30 mins in dark at RT. The samples were analyzed using LSRFortessa (BD Biosciences) flow cytometer.
[0022] Western blot. MCL (parental or Ibrutinib resistant), EC, or NSCLC cells were plated in 6cm or 10 cm tissue culture dishes at a cell density of 3-5x106and incubated overnight. MCL cells were serum starved for 6 h and then treated in the presence of increasing concentration of SRX3305 or Ibrutinib for 1 h, followed by stimulation with 10 pg / mL of goat F(ab)2 anti-human antibody (Southern Biotech, Birmingham, Cat # 2022-01) for 15 min at 37 °C. EC and NSCLC cells were treated with the indicated concentrations of LCI130-series chemotype or the indicated single agent control for 24 h. Whole cell lysates of the treated and untreated cells were prepared using RIPAbuffer supplemented with protease, phosphatase / protease inhibitor cocktails (Cell signaling). Protein concentration in cell lysates was determined using a bicinchoninic acid (BCA) assay kit (Thermo Fisher). Equal amounts of lysate were resolved on a 4-12% SDS-PAGE, transferred to nitrocellulose membranes, and probed with one or more of the following antibodies: anti-pAKT- S473 (Cat # 9271 S), total anti-AKT (Cat # 4691), and anti-β-actin (Cat # SC69879). Secondary antibodies were chosen according to the species of origin of the primary antibody. Protein bands were detected using the Pierce enhanced chemiluminescence (ECL) substrate (Thermo Fisher) and imaging system.
[0023] BCR Pathway stimulation. JeKo-1, Mino cells (5x 106) were serum starved for 6 h and then incubated with or without ribociclib, BKM-120, PLX51107, LCI28 LCI133, and LCI132 or controls for 1 h. Treated cells were then resuspended in 1 mL of RPMI1640, supplemented with 20% FBS and stimulated with 10 pg / mL of goat F(ab’)2 anti-human IgM antibody at 37 °C for 10 min. Stimulated cells were harvested and lysed with RIPA buffer followed by western blot analysis for pAKT, pRB, pERK and c-MYC.
[0024] In vivo mouse tumor model. 0.5e6 murine A20 B cell lymphoma (BCL) cells were injected into Balb / c mice, animals monitored for weight and tumor growth according to approved IACUC protocol, and tumors grown to 100 mm3. Once tumors reached appropriate size, animals were randomized into two groups and treated IP with vehicle control or LCI132 (40 mg / kg) QD for 17 days. On the 18thday when vehicle animals reached human endpoint, all animals were humanely sacrificed according to approved IACUC protocol and tumors were measured for final volume and weight.References:(1) Vaandrager, J. W.; Schuuring, E.; Zwikstra, E.; de Boer, C. J.; Kleiverda, K. K.; van Krieken, J. H.; Kluin-Nelemans, H. C.; van Ommen, G. J.; Raap, A. K.; Kluin, P. M. Direct visualization of dispersed 11 q 13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 1996, 88 (4), 1177-1182. From NLM Medline.(2) Fu, S.; Wang, M.; Lairson, D. R.; Li, R.; Zhao, B.; Du, X. L. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget 2017, 8 (68), 112516-112529. DOI: 10.18632 / oncotarget.22367 From NLM PubMed-not-MEDLINE.(3) Dreyling, M.; Campo, E.; Hermine, O.; Jerkeman, M.; Le Gouill, S.; Rule, S.; Shpilberg, O.; Walewski, J.; Ladetto, M.; Committee, E. G. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017, 28 (suppl_4), iv62-iv71. DOI: 10.1093 / annonc / mdx223 From NLM Medline.(4) Kumar, A.; Sha, F.; Toure, A.; Dogan, A.; Ni, A.; Batlevi, C. L.; Palomba, M. L. M.; Portlock, C.; Straus, D. J.; Noy, A.; et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J 2019, 9 (6), 50. DOI: 10.1038 / s41408-019-0209-5 From NLM Medline.(5) Riedell, P. A.; Hamadani, M.; Ahn, K. W .; Litovich, C.; Murthy, G. S. G.; Locke, F. L.; Brunstein, C. G.; Merryman, R. W.; Stiff, P. J.; Pawarode, A.; et al. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther 2021, 27 (11), 911 e911-911 e917. DOI: 10.1016 / j .jtct.2021.08.014 From NLM Medline.(6) Le Gouill, S.; Thieblemont, C.; Oberic, L.; Moreau, A.; Bouabdallah, K.; Dartigeas, C.; Damaj, G.; Gastinne, T.; Ribrag, V.; Feugier, P.; et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. A Engl J Med 2017, 377 (13), 1250-1260. DOI: 10.1056 / NEJMoal701769 From NLM Medline.(7) Narkhede, M.; Goyal, G.; Shea, L.; Mehta, A.; Giri, S. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv 2022, 6 (14), 4122-4131. DOI: 10.1182 / bloodadvances.2022007247 From NLM Medline.(8) Lee, C.; Martin, P. Watch and Wait in Mantle Cell Lymphoma. Hematol Oncol Clin North Am 2020, 34 (5), 837-847. DOI: 10.1016 / j .hoc.2020.06.002 From NLM Medline.(9) Klapper, W. Histopathology of mantle cell lymphoma. Semin Hematol 2011, 48 (3), 148-154. DOI: 10.1053 / j.seminhematol.2011.03.006 From NLM Medline.(10) Lee, C.; Huang, X.; Di Liberto, M.; Martin, P.; Chen-Kiang, S. Targeting CDK4 / 6 in mantle cell lymphoma. Ann Lymphoma 2020, 4. DOI: 10.21037 / aol.2019.12.01 From NLM PubMed- not-MEDLINE.(11) Duan, Y. C.; Zhang, S. J.; Shi, X. J.; Jin, L. F.; Yu, T.; Song, Y .; Guan, Y. Y. Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. Eur J Med Chem 2021, 222, 113588. DOI: 10.1016 / j. ejmech.2021.113588 From NLM Medline.(12) Guo, Z.; Sun, Y.; Liang, L.; Lu, W .; Luo, B.; Wu, Z.; Huo, B.; Hu, Y.; Huang, P.; Wu, Q.; et al. Design and Synthesis of Dual EZH2 / BRD4 Inhibitors to Target Solid Tumors. J Med Chem 2022, 65 (9), 6573-6592. DOI: 10.1021 / acs.jmedchem.lc01876 From NLM Medline.(13) Lu, D.; Wang, C.; Qu, L.; Yin, F.; Li, S.; Luo, H.; Zhang, Y.; Liu, X.; Chen, X.; Luo, Z.; et al. Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. J Med Chem 2022, 65 (19), 12838-12859. DOI: 10.1021 / acs.jmedchem.2c00673 From NLM Medline.(14) Mazur, P. K.; Herner, A.; Mello, S. S.; Wirth, M.; Hausmann, S.; Sanchez-Rivera, F. J.; Lofgren, S. M.; Kuschma, T.; Hahn, S. A.; Vangala, D.; et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 2015, 21 (10), 1163-1171. DOI: 10.1038 / nm.3952 From NLM Medline.(15) Huang, X.; Yan, J.; Zhang, M.; Wang, Y.; Chen, Y.; Fu, X.; Wei, R.; Zheng, X. L.; Liu, Z.; Zhang, X.; et al. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2- Aberrant Solid Tumors. Cell 2018, 175 (1), 186-199 el 19. DOI: 10.1016 / j cell.2018.08.058 From NLM Medline.(16) Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 2014, 57 (19), 7874-7887. DOI: 10.1021 / jm5006463 From NLM Medline.(17) Wang, C.; Qu, L.; Li, S.; Yin, F.; Ji, L.; Peng, W.; Luo, H.; Lu, D.; Liu, X.; Chen, X.; et al.Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA. J Med Chem 2021, 64 (17), 12630-12650. DOI:10.1021 / acs.jmedchem. lc00567 From NLM Medline.(18) Franco, L. C.; Morales, F.; Boffo, S.; Giordano, A. CDK9: A key player in cancer and other diseases. J Cell Biochem 2018, 119 (2), 1273-1284. DOI: 10.1002 / jcb.26293 From NLM Medline.(19) Lee, D. J.; Zeidner, J. F. Cyclin-dependent kinase (CDK) 9 and 4 / 6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. Expert Opin Investig Drugs 2019, 28 (11), 989-1001. DOI: 10.1080 / 13543784.2019.1678583 From NLM Medline.(20) Minzel, W .; Venkatachalam, A.; Fink, A.; Hung, E.; Brachya, G.; Burstain, I.; Shaham, M.; Rivlin, A.; Omer, I.; Zinger, A.; et al. Small Molecules Co-targeting CKIalpha and the Transcriptional Kinases CDK7 / 9 Control AML in Preclinical Models. Cell 2018, 175 (1), 171-185 el25. DOI: 10.1016 / j cell.2018.07.045 From NLM Medline.(21) Cannon, L.; Academia, E. C.; Glode, A. E. A Review of PI3K Inhibitors in B-Cell Malignancies. J Adv Pract Oncol 2019, 10 (7), 715-725. DOI: 10.6004 / jadpro.2019.10.7.7 From NLM PubMed-not-MEDLINE.(22) Huang, X.; Liu, G.; Guo, J.; Su, Z. The PI3K / AKT pathway in obesity and type 2 diabetes. Int JBiolSci 2018, 14 (11), 1483-1496. DOI: 10.7150 / ijbs.27173 From NLM Medline.(23) Chiron, D.; Martin, P.; Di Liberto, M.; Huang, X.; Ely, S.; Lannutti, B. J.; Leonard, J. P.; Mason, C. E.; Chen-Kiang, S. Induction of prolonged early G1 arrest by CDK4 / CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IPL Cell Cycle 2013, 72 (12), 1892-1900. DOI: 10.4161 / cc.24928 From NLM Medline.(24) Divakar, S. K.; Ramana Reddy, M. V.; Cosenza, S. C.; Baker, S. J.; Perumal, D.; Antonelli, A. C.; Brody, J.; Akula, B.; Parekh, S.; Reddy, E. P. Dual inhibition of CDK4 / Rb and PI3K / AKT / mT0R pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia 2016, 30 (1), 86-93. DOI: 10.1038 / leu.2015.185 From NLM Medline.(25) Tsukamoto, T.; Nakahata, S.; Sato, R.; Kanai, A.; Nakano, M.; Chinen, Y.; Maegawa-Matsui, S.; Matsumura-Kimoto, Y.; Takimoto-Shimomura, T.; Mizuno, Y.; et al. BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. Cancer Genomics Proteomics 2020, 17 (1), 77-89. DOI: 10.21873 / cgp.20169 From NLM Medline.(26) Gramec, D.; Peterlin Masic, L.; Sollner Dolenc, M. Bioactivation potential of thiophenecontaining drugs. Chem Res Toxicol 2014, 27 (8), 1344-1358. DOI: 10.1021 / tx500134g From NLM Medline.(27) Chen, W.; Caceres-Cortes, J.; Zhang, H.; Zhang, D.; Humphreys, W. G.; Gan, J. Bioactivation of substituted thiophenes including alpha-chlorothiophene-containing compounds in human liver microsomes. Chem Res Toxicol 2011, 24 (5), 663-669. DOI: 10.1021 / txl00386z From NLM Medline.(28) Hutzler, J. M.; Balogh, L. M.; Zientek, M.; Kumar, V.; Tracy, T. S. Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+ / -)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos 2009, 37 (1), 59-65. DOI: 10.1124 / dmd.108.023358 From NLM Medline.(29) Jaladanki, C. K.; Taxak, N.; Varikoti, R. A.; Bharatam, P. V. Toxicity Originating from Thiophene Containing Drugs: Exploring the Mechanism using Quantum Chemical Methods. Chem Res Toxicol 2015, 28 (12) , 2364-2376. DOI: 10.1021 / acs.chemrestox.5b00364 From NLM Medline.(30) Burgoyne, A. M.; Vann, K. R.; Joshi, S.; Morales, G. A.; Vega, F. M.; Singh, A.; Pal, D.; Merati, A. B.; Kutateladze, T. G.; Durden, D. L. A triple action CDK4 / 6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov 2020, 6 (1), 49. DOI: 10.1038 / s41421-020-0181- z From NLM PubMed-not-MEDLINE.(31) Park, B. K.; Boobis, A.; Clarke, S.; Goldring, C. E.; Jones, D.; Kenna, J. G.; Lambert, C.; Laverty, H. G.; Naisbitt, D. J.; Nelson, S.; et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011, 10 (4), 292-306. DOI: 10.1038 / nrd3408 From NLM Medline.(32) Joshi, S.; Liu, K. X.; Zulcic, M.; Singh, A. R.; Skola, D.; Glass, C. K.; Sanders, P. D.; Sharabi, A. B.; Pham, T. V.; Tamayo, P.; et al. Macrophage Syk-PI3Kgamma Inhibits Antitumor Immunity:SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther 2020, 19 (3), 755-764. DOI: 10.1158 / 1535-7163.MCT-19-0947 From NLM Medline.(33) Gaspar, A.; Matos, M. J.; Garrido, J.; Uriarte, E.; Borges, F. Chromone: a valid scaffold in medicinal chemistry. Chem Rev 2014, 114 (9), 4960-4992. DOI: 10.1021 / cr400265z From NLM Medline.(34) Chen, P.; Lee, N. V.; Hu, W .; Xu, M.; Ferre, R. A.; Lam, H.; Bergqvist, S.; Solowiej, J.; Diehl, W.; He, Y. A.; et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther 2016, 15 (10), 2273-2281. DOI: 10.1158 / 1535-7163.MCT-16- 0300 From NLM Medline.(35) Andrews, F. H.; Singh, A. R.; Joshi, S.; Smith, C. A.; Morales, G. A.; Garlich, J. R.; Durden, D. L.; Kutateladze, T. G. Dual -activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A 2017, 114 (7), E1072-E1080. DOI: 10.1073 / pnas.1613091114 From NLM Medline.(36) Abbott, B. M.; Thompson, P. E. PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorg Med Chem Let 2004, 14 (11), 2847-2851. DOI: 10.1016 / j.bmcl.2004.03.043 From NLM Medline.(37) Li, Y.; Luo, X.; Guo, Q.; Nie, Y.; Wang, T.; Zhang, C.; Huang, Z.; Wang, X.; Liu, Y.; Chen, Y.; et al. Discovery of Nl-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4 / 9 (CDK4 / 9) and Histone Deacetlyasel (HDAC1) against Malignant Cancer. J Med Chem 2018, 61 (7), 3166-3192. DOI: 10.1021 / acs.jmedchem.8b00209 From NLM Medline.(38) Anshabo, A. T.; Milne, R.; Wang, S.; Albrecht, H. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Front Oncol 2021, 77, 678559. DOI: 10.3389 / fonc.202l 678559 From NLM PubMed-not-MEDLINE.The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Claims
What is claimed is:
1. A compound of Formula I:Formula I or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1is an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andX1and X2are each independently selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
2. The compound of claim 1, wherein the compound of Formula I is a compound ofFormula I A:Formula IA or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1is an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andX1and X2are each independently selected from the group consisting of C and N,which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
3. The compound of claim 2, wherein the compound of Formula IA is a compound of Formula IA(a):Formula IA(a) or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H, alkyl, or hydroxy;X2and X3are each independently selected from the group consisting of C and N;R4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl .
4. The compound of claim 3, wherein the compound of Formula IA is a compound of Formula IA(a)(i):Formula IA(a)(i)or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;X2is selected from the group consisting of C and N;R2is H or hydroxy;R4 is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); andX3is selected from the group consisting of C and N.
5. The compound of claim 4, wherein the compound is selected from the group consistingor a pharmaceutically acceptable salt thereof.
6. The compound of claim 4, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
7. The compound of claim 2, wherein the compound of Formula IA is a compound ofFormula IA(b):Formula IA(b) or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;X1and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH;R4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl); and two of R5, R6, and R7join to form a heterocycle, and the third is H or alkyl.
8. The compound of claim 7, wherein the compound of Formula IA(b) is a compound of Formula IA(b)(i):Formula IA(b)(i) or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H or hydroxy;X3is selected from the group consisting of C and N; andR4is selected from the group consisting of H, alkyl, halo, hydroxy, carboxy, and haloalkyl (e.g., trifluoromethyl).
9. The compound of claim 8, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
10. The compound of claim 8, wherein the compound is selected from the group consistingor a pharmaceutically acceptable salt thereof.
11. The compound of claim 7, wherein the compound of Formula IA(b) is a compound ofFormula IA(b)(ii):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Xi is N and R2is absent, or Xi is C and R2is H or hydroxy;X3is C or N; andY is selected from the group consisting of O and NH.
12. The compound of claim 11, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
13. The compound of claim 11, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
14. The compound of claim 2, wherein the compound of Formula IA is a compound ofFormula IA(c):Formula IA(c) or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H or hydroxy;X1is selected from the group consisting of C and N;(i) two of R4, RS, and R6join to form a heterocycle, and the third is H; or (ii) two of R5, R6, and R7are H or alkyl, and the third is a heterocycle; andR7is selected from the group consisting of H, alkyl, carbonyl, and alkenyl.
15. The compound of claim 14, wherein the compound is selected from the group consistingor a pharmaceutically acceptable salt thereof.
16. The compound of claim 14, wherein the compound is:or a pharmaceutically acceptable salt thereof.
17. The compound of claim 14, wherein R7is an α,β-unsaturated carbonyl, such as:or a pharmaceutically acceptable salt thereof.
18. The compound of claim 2, wherein the compound of Formula IA is a compound of Formula IA(d):Formula IA(d) or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:X1is selected from the group consisting of C and N;R2is H or hydroxy;R4, R5, and R6are independently selected from the group consisting of H, halo (e.g., Cl), hydroxy, and alkoxy; and two of R7, R8, and R9join to form a heterocycle, and the third is H or alkyl.
19. The compound of claim 18, wherein the compound is selected from the group consistingor a pharmaceutically acceptable salt thereof.
20. The compound of claim 18, wherein the compound is:or a pharmaceutically acceptable salt thereof.
21. The compound of claim 1, wherein the compound of Formula I is a compound ofFormula IB:or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andX1is selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluorom ethyl).
22. The compound of claim 21, wherein R3is heteroaryl.
23. The compound of claim 21, wherein the compound of Formula IB is a compound ofFormula IB (a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H, alkyl, or hydroxy; and two of R4, R5, and R6join to form an aryl, heteroaryl or heterocycle, and the third is H or alkyl.
24. The compound of claim 23, wherein the compound of Formula IB(a) is a compound ofFormula IB(a)(i) :or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:Y is selected from the group consisting of O and NH;R2is H, alkyl, or hydroxy;R7is selected from the group consisting of H, alkyl, alkoxy, cyano, amino and amide; andX3and X4 are each independently selected from the group consisting of C and N.
25. The compound of claim 24, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
26. The compound of claim 23, wherein the compound is:or a pharmaceutically acceptable salt thereof.
27. The compound of claim 22, wherein the compound of Formula IB is a compound of Formula IB(b):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;R4is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide;R5and R6are each independently selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl);X2and X3are each independently selected from the group consisting of C and N; when X2is N, R5is absent; andY is selected from the group consisting of O and NH.
28. The compound of claim 27, wherein the compound of Formula IB(b) is a compound of Formula IB(b)(i):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;Y is selected from the group consisting of O and NH;X2is selected from the group consisting of C and N; when X2is N, R5is absent;R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); and one of R7and R8is H or alkyl, and the other is selected from the group consisting of cycloalkyl, heterocycle, aryl, and heteroaryl, or R7and R8join to form a heterocycle.
29. The compound of claim 28, wherein the compound of Formula IB(b)(i) is a compound of Formula IB(b)(i)(x):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;Y is selected from the group consisting of O and NH;R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl);X2is selected from the group consisting of C and N; when X2is N, R5is absent; and two of R9, R10, and R11join to form a heterocycle, and the third is H or alkyl.
30. The compound of claim 29, wherein the compound of Formula IB(b)(i) is a compound ofFormula IB(b)(i)(x)(a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;R5is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl);X2is selected from the group consisting of C and N; when X2is N, R5is absent; andY is selected from the group consisting of O and NH.
31. The compound of claim 30, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
32. The compound of claim 30, wherein the compound is selected from the group consistingor a pharmaceutically acceptable salt thereof.
33. The compound of claim 30, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
34. The compound of claim 27, wherein the compound of Formula IB(b) is a compound ofFormula IB(b)(ii):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl);X2and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH; and one of R7and R8is H or alkyl, and the other is selected from the group consisting of cycloalkyl, heterocycle, aryl, and heteroaryl, or R7and R8join to form a heterocycle.
35. The compound of claim 34, wherein the compound of Formula IB(b)(ii) is a compound of Formula IB(b)(ii)(x):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;X2and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH; R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., trifluoromethyl); and two of R9, R10, and R11join to form a heterocycle, and the third is H or alkyl.
36. The compound of claim 35, wherein the compound of Formula IB(b)(ii)(x) is a compound of Formula IB(b)(ii)(x)(a):or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R2is H, alkyl, or hydroxy;X2and X3are each independently selected from the group consisting of C and N;Y is selected from the group consisting of O and NH; and R6is selected from the group consisting of H, hydroxy, carboxy, halo, and haloalkyl (e.g., tri fluoromethyl).
37. The compound of claim 34, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
38. The compound of claim 34, wherein the compound is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.
39. The compound of claim 21, wherein the compound is:or a pharmaceutically acceptable salt thereof.
40. The compound of claim 21, wherein the compound is:or a pharmaceutically acceptable salt thereof.
41. The compound of claim 1, wherein the compound of Formula I is a compound ofFormula IC:or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof, wherein:R1is an aryl, heteroaryl, or heterocycle;R2is H, alkyl, or hydroxy; R3is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycle, amine, and amide; andX1is selected from the group consisting of C and N, which formula may be optionally substituted one, two or three times, e.g., with independently selected halo (e.g., fluoro), lower alkyl (e.g. methyl), or haloalkyl (e.g., fluoromethyl, difluoromethyl or trifluoromethyl).
42. The compound of claim 41, wherein the compound is:or a pharmaceutically acceptable salt thereof.
43. A method of treatment for cancer comprising administering the compound of any one of claims 1-42 to a subject in need thereof wherein said compound is provided in a therapeutically effective amount.
44. The method of claim 43, wherein the cancer is a lymphoma, a leukemia, a melanoma, a blastoma, a sarcoma, a myeloma, a glioma, and / or a germ cell tumor.
45. The method of claim 43 or 44, wherein the cancer is adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia / lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma,dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangio sarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visualpathway glioma, vulvar cancer, vaginal cancer, Waldenstrom macroglobulinemia, Warthin's tumor, and Wilms' tumor.
46. The method of any one of claims 43-45, wherein the cancer is mantle cell lymphoma.
47. The method of any one of claims 43-46, wherein the subject is a human subject.
48. The method of any one of claims 43-46, wherein the subject is a non-human mammalian subject (e.g., a dog, cat, horse, or livestock animal).
49. The method of any one of claims 43-48, wherein the administering further comprises administering an anti-cancer therapeutic (e.g., a chemotherapeutic and / or an immunotherapeutic) to the subject.
50. A method of treatment for disease comprising administering the compound of any one of claims 1-42 to a subject in need thereof wherein said compound is provided in a therapeutically effective amount.
51. The method of claim 50, wherein the disease is associated with aberrant CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein activity.
52. The method of claim 50 or 51, wherein the compound inhibits at least one of the CDK (e.g., CDK4, CDK6, and / or CDK9), PI3K, and / or bromodomain protein.
53. The method of claim 50, wherein the disease is non-cancer proliferative disease, sepsis, autoimmune disease, infection, atherosclerosis, Type I or 2 diabetes, obesity, inflammatory disease, fibrotic disease, neurodegenerative disease, organ system degenerative disease, aberrant transcriptome / epigenetic disease, and / or a metabolic or Myc-dependent disorder.
54. The method of claim 53, wherein the non-cancer proliferative disease is meningioma, cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, multiple endocrine neoplasia, nasal polyps, pituitary tumors, juvenile polyposis syndrome, prolactinoma, pseudotumor benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, vocal cord nodules, polyps, and cysts,chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, and / or Castleman disease.
55. The method of claim 53, wherein the non-cancer proliferative disease is a fibrotic disease (IPF) or post-ischemic reperfusion injury to all organs including brain, lung, kidney, heart, liver, pancreas, spinal cord, etc.
56. The method of claim 53, wherein the inflammatory disease is appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, psoriasis, allergy, Crohn's disease, irritable bowel syndrome, ulcerative colitis, inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, autoimmune polyglandular disease / syndrome, autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, hepatitis, gastritis, enteritis, dermatitis, gingivitis, Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, Type I diabetes, septic shock, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Graves' disease, Guillain-Barre syndrome, Behcet's disease, scleroderma, mycosis fungoides, graft versus host disease, irritable bowel syndrome, psoriasis, acute respiratory distress syndrome and / or ischemia / reperfusion injury.
57. The method of claim 53, wherein the disease is a viral infection.
58. The method of claim 57, wherein the viral infection is a coronavirus infection (e.g., COVID-19), herpesvirus infection, adenovirus infection, Epstein-Barr virus infection, Ebola virus infection, human papilloma virus infection, cytomegalovirus infection, influenza virus infection, respiratory syncytial virus infection, rhinovirus infection, hepatovirus injection (e.g., hepatovirus A, hepatovirus B, hepatovirus C, hepatovirus D, and / or hepatovirus E), West Nile virus infection, alphavirus infection, and / or human immunodeficiency virus infection.
59. The method of claim 53, wherein the pathophysiological mechanisms of the disease comprise a reduced activity of the innate or adaptive immune response (including immunosuppression mediated by inhibitory leukocytes including anti-cancer immunity), or wherein the pathologic mechanisms of the disease comprise an augmented innate or adaptive immune response (e.g., autoimmunity) (including but not limited to tolerance, T cell exhaustion, lack of response to chronic infectious agents (e.g. tuberculosis, parasitic infections or resistant bacterial or viral infections)).
60. A composition comprising a compound of any one of claims 1-42 and a pharmaceutically acceptable carrier.
61. The composition of claim 60, formulated for oral, parenteral, intra-tumoral or intra-organ administration.
Citation Information
Patent Citations
Lead pencil
CA215651A
Thienopyranones and furanopyranones as checkpoint inhibitors and modulators of anti-tumor immunity
US11472814B2
Thienopyranones as Kinase and Epigenetic Inhibitors
US20170334925A1
Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof
US20210300939A1
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4 / 6) inhibitor and an MTOR inhibitor for treating cancer
WO2011130232A1
